

**Maternal supplementation with *Bacillus altitudinis* spores improves porcine offspring growth performance and carcass weight.**

Journal:	<i>British Journal of Nutrition</i>
Manuscript ID	BJN-RA-20-1293.R1
Manuscript Type:	Research Article
Date Submitted by the Author:	n/a
Complete List of Authors:	Crespo-Piazuelo, Daniel; TEAGASC, Pig Development Department Gardiner, Gillian; Waterford Inst. of Technology, Department of Science Ranjitkar, Samir; TEAGASC, Pig Development Department Bouwhuis, Meike; TEAGASC, Pig Development Department Ham, Rebecca; Waterford Inst. of Technology, Department of Science Phelan, John; Waterford Inst. of Technology, Department of Science Marsh, Alan; Waterford Inst. of Technology, Department of Science Lawlor, Peadar; TEAGASC, Pig Development Department
Keywords:	probiotic, sow, swine, small intestinal morphology, colostrum
Subject Category:	Microbiology
Abstract:	<p>The objective of this study was to evaluate the effect of feeding <i>Bacillus altitudinis</i> spores to sows and/or offspring on growth and health indicators. On day (D) 100 of gestation, 24 sows were selected and grouped as: control (CON), fed with a standard diet; and probiotic (PRO), fed the standard diet supplemented with <i>B. altitudinis</i> WIT588 spores from D100 of gestation until weaning. Offspring (n=144) from each of the two sow treatments were assigned to either a CON (no probiotic) or PRO (<i>B. altitudinis</i>-supplemented) treatment for 28 days post-weaning (pw), resulting in four treatment groups: 1) CON/CON, non-probiotic supplemented sow/non-probiotic supplemented piglet; 2) CON/PRO, non-probiotic supplemented sow/probiotic-supplemented piglet; 3) PRO/CON, probiotic-supplemented sow/non-probiotic supplemented piglet; 4) PRO/PRO, probiotic-supplemented sow/probiotic-supplemented piglet. <i>Bacillus altitudinis</i> WIT588 was detected in the faeces of probiotic-supplemented sows and their piglets, and in the faeces and intestine of probiotic-supplemented piglets. Colostrum from PRO sows had higher total solids (P=0.02), protein (P=0.04), and true protein (P=0.05), and lower lactose (P&lt;0.01) than colostrum from CON sows. Maternal treatment improved offspring feed conversion ratio at D0-14 pw (P&lt;0.001) and increased offspring bodyweight at D105 and D127 pw (P=0.01), carcass weight (P=0.05) and kill-out percentage (P&lt;0.01). It also increased small intestinal absorptive capacity and impacted the haematological profile of sows and progeny. Little impact of post-weaning treatment was observed on any of the parameters measured. Overall, the lifetime growth benefits in the offspring of <i>B. altitudinis</i>-supplemented sows offer considerable economic advantages for pig producers in search of alternatives to in-feed antibiotics/zinc oxide.</p>

SCHOLARONE™  
Manuscripts

1  
2 **Maternal supplementation with *Bacillus altitudinis* spores improves porcine**  
3 **offspring growth performance and carcass weight**

4  
5  
6  
7 Daniel Crespo-Piazuelo<sup>1</sup>†, Gillian E. Gardiner<sup>2</sup>†\*, Samir Ranjitkar<sup>1</sup>, Meike A.  
8 Bouwhuis<sup>1</sup>, Rebecca Ham<sup>2</sup>, John P. Phelan<sup>2</sup>, Alan Marsh<sup>2</sup>, and Peadar G. Lawlor<sup>1</sup>

9  
10 <sup>1</sup>Pig Development Department, Animal and Grassland Research and Innovation Centre,  
11 Teagasc, Moorepark, Fermoy, Co. Cork, Ireland.

12 <sup>2</sup>Eco-Innovation Research Centre, Department of Science, Waterford Institute of  
13 Technology, Waterford, Ireland.

14  
15 †These authors contributed equally to this work.

16  
17 \*Corresponding author: Gillian Gardiner, +353 51 302626, [ggardiner@wit.ie](mailto:ggardiner@wit.ie)

18  
19  
20 **Running head:** Maternal and post-weaning supplementation with probiotic spores

21  
22 **Key words:** probiotic, sow, pig, swine, small intestinal morphology, colostrum

26 **Abstract**

27 The objective of this study was to evaluate the effect of feeding *Bacillus altitudinis*  
28 spores to sows and/or offspring on growth and health indicators. On day (D) 100 of  
29 gestation, 24 sows were selected and grouped as: control (CON), fed with a standard  
30 diet; and probiotic (PRO), fed the standard diet supplemented with *B. altitudinis*  
31 WIT588 spores from D100 of gestation until weaning. Offspring (n=144) from each of  
32 the two sow treatments were assigned to either a CON (no probiotic) or PRO (*B.*  
33 *altitudinis*-supplemented) treatment for 28 days post-weaning (pw), resulting in four  
34 treatment groups: 1) CON/CON, non-probiotic supplemented sow/non-probiotic  
35 supplemented piglet; 2) CON/PRO, non-probiotic supplemented sow/probiotic-  
36 supplemented piglet; 3) PRO/CON, probiotic-supplemented sow/non-probiotic  
37 supplemented piglet; 4) PRO/PRO, probiotic-supplemented sow/probiotic-  
38 supplemented piglet. *Bacillus altitudinis* WIT588 was detected in the faeces of  
39 probiotic-supplemented sows and their piglets, and in the faeces and intestine of  
40 probiotic-supplemented piglets. Colostrum from PRO sows had higher total solids  
41 ( $P=0.02$ ), protein ( $P=0.04$ ), and true protein ( $P=0.05$ ), and lower lactose ( $P<0.01$ ) than  
42 colostrum from CON sows. Maternal treatment improved offspring feed conversion  
43 ratio at D0-14 pw ( $P<0.001$ ) and increased offspring bodyweight at D105 and D127 pw  
44 ( $P=0.01$ ), carcass weight ( $P=0.05$ ) and kill-out percentage ( $P<0.01$ ). It also increased  
45 small intestinal absorptive capacity and impacted the haematological profile of sows  
46 and progeny. Little impact of post-weaning treatment was observed on any of the  
47 parameters measured. Overall, the lifetime growth benefits in the offspring of *B.*  
48 *altitudinis*-supplemented sows offer considerable economic advantages for pig  
49 producers in search of alternatives to in-feed antibiotics/zinc oxide.

50

## 51 **Introduction**

52 Stress at weaning can negatively impact piglet immunity and gut health, impairing  
53 growth and feed efficiency and often resulting in diarrhoea<sup>(1)</sup>. Along with the stress of  
54 weaning, passive immunity of the piglets is also reduced at this time, while active  
55 immunity is not fully developed. This makes weaned pigs more prone to disease<sup>(2)</sup>, in  
56 particular post-weaning diarrhoea which can be caused by enterotoxigenic *Escherichia*  
57 *coli*<sup>(3)</sup> or other pathogens<sup>(4)</sup>. To reduce the incidence of these pathogens and the  
58 occurrence of post-weaning diarrhoea and to prevent the weaning-associated growth  
59 check, in-feed antibiotic and/or zinc oxide treatments are frequently used<sup>(5)</sup>. However,  
60 following the ban of in-feed antibiotic growth promoters in the European Union (EU) in  
61 2006, a ban on the preventive use of antibiotics in groups of animals and via medicated  
62 feed will enter into force in the EU in 2022. In the same year, the use of  
63 pharmacological levels of zinc oxide will also be banned. As a result, alternative  
64 treatments, such as probiotics will be of increased importance in the future. Probiotics  
65 not only control pathogens, but they can also improve pig growth and feed  
66 efficiency<sup>(5,6)</sup>.

67 Bacteria from *Bacillus* spp. are commonly used as probiotics in pig production<sup>(7-9)</sup>.  
68 Species from this genus form spores, which increases their resistance to hostile  
69 conditions such as those encountered in the gastrointestinal tract and during feed  
70 manufacture<sup>(10,11)</sup>. In addition, the vegetative cells of *Bacillus* spp. produce extracellular  
71 enzymes, which can increase nutrient availability in the diet and improve  
72 digestibility<sup>(12)</sup>, and *Bacillus* are well-known for the production of antimicrobials<sup>(13-15)</sup>.  
73 On this basis, many studies which administered spores of *Bacillus* spp. to weaned pigs  
74 found improved growth performance and feed conversion<sup>(16-18)</sup>, while the incidence of  
75 post-weaning diarrhoea was also reduced in some cases<sup>(19)</sup>. Nevertheless, commencing  
76 the administration of *Bacillus* spores to pigs post-weaning may not be the most effective  
77 strategy. Firstly, it may be too late, as evidence suggests that early-life gut microbiota  
78 interventions are more effective<sup>(20-25)</sup>. Secondly, the spores may not germinate in the  
79 gastrointestinal tract<sup>(26)</sup>; and lastly, which may/may not be related to lack of  
80 germination, *Bacillus* administered as spores do not usually persist for more than one  
81 week after ceasing administration<sup>(12)</sup>.

82 A cheaper and potentially more effective alternative to probiotic supplementation of  
83 post-weaning diets is the inclusion of *Bacillus* spores in the diet of gestating and/or

84 lactating sows. Vertical transmission of the probiotic from sows to their offspring then  
85 occurs between birth and weaning<sup>(27,28)</sup>, although this is sometimes limited<sup>(29)</sup>. Maternal  
86 administration can also benefit the sow, minimizing weight loss during lactation and  
87 improving reproductive performance and milk quality<sup>(18,20,30,31)</sup>. These maternal  
88 benefits sometimes increase the number of piglets weaned per sow<sup>(30)</sup>, although some  
89 studies did not find any significant effects on sow productivity<sup>(22,24,27,28)</sup>. Probiotic  
90 administration to sows also leads to improved weight gain and feed efficiency in the  
91 offspring post-weaning<sup>(18,20,22,28)</sup>. However, the mechanisms by which maternal  
92 probiotic supplementation benefits offspring growth are not fully understood. Probiotic  
93 administration stimulates the immune system of sows, which confers passive immunity  
94 to offspring through colostrum and milk<sup>(32)</sup>. Stimulation of the immune system of the  
95 piglets may even start before the piglets are born, as piglets become immunocompetent  
96 *in utero* and their active immunity depends on maternal antibody levels<sup>(33)</sup>.  
97 Furthermore, the faecal bacterial community of the sows, including any administered  
98 probiotic and/or probiotic-modulated taxa, can be transferred to their litter through the  
99 intake of maternal faeces<sup>(28)</sup>.

100 However, most studies that administer probiotics to gestating/lactating sows do not  
101 follow the growth of offspring beyond the weaner stage, as they are usually focused on  
102 the incidence of post-weaning diarrhoea<sup>(7,18,20,24,27–29,31)</sup>. The aim of the present study  
103 was therefore to evaluate the efficacy of a novel *Bacillus altitudinis* probiotic delivered  
104 as spores to sows and/or their offspring on sow health, reproductive performance and  
105 colostrum quality, as well as on lifetime growth and health and carcass characteristics of  
106 the offspring.

107

## 108 **Materials and Methods**

### 109 ***Ethical approval***

110 Ethical approval for this study was granted by the Teagasc Animal Ethics Committee  
111 (approval no. TAEC148/2017) and the project was authorised by the Health Products  
112 Regulatory Authority (project authorisation no. AE19132/P066). The experiment was  
113 conducted in accordance with Irish legislation (SI no. 543/2012) and the EU Directive  
114 2010/63/EU for animal experimentation.

115

### 116 *Experimental design and diets*

117 A total of 24 sows (Large White × Landrace; Hermitage Genetics, Sion Road, Co.  
118 Kilkenny, Ireland) were selected on day 100 (D) 100 of gestation and blocked by parity,  
119 body weight (BW) and back fat (BF) depth, following which they were individually  
120 housed and randomly assigned to one of two experimental treatment groups as follows:  
121 1) control (CON,  $n=12$ ), fed with a standard gestation diet from D100 of gestation to  
122 farrowing, followed by a standard lactation diet for 26 days until litters were weaned;  
123 and 2) probiotic (PRO,  $n=12$ ), fed the standard gestation/lactation diet supplemented  
124 with *B. altitudinis* WIT588 spores ( $\sim 4 \times 10^9$  spores daily from D100 of gestation to  
125 farrowing and  $\sim 1.2 \times 10^{10}$  spores daily during lactation for 26 days until weaning of  
126 litters, administered as outlined below). Cross-fostering of piglets was performed  
127 between 24 and 48 h *post-partum* to equalize litter size (14 piglets/litter) if necessary,  
128 but only within the same treatment group.

129 At weaning (at  $D26 \pm 1.5$  of age), a total of 144 piglets from these sows ( $n=72$ /sow  
130 treatment) were selected across all litters, blocked by sow treatment, sex, BW and litter  
131 origin and randomly assigned to dietary treatments. Offspring from each of the two sow  
132 treatments were assigned as same gender pairs of pigs to either a CON (no probiotic) or  
133 PRO (probiotic-supplemented) treatment for 28 days post-weaning (pw), resulting in  
134 four treatment groups ( $n=36$  piglets/treatment) as follows: 1) piglets weaned from CON  
135 sows, fed a CON diet (CON/CON); 2) piglets weaned from CON sows, fed a probiotic-  
136 supplemented diet (CON/PRO); 3) piglets weaned from PRO sows, fed a CON diet  
137 (PRO/CON); and 4) piglets weaned from PRO sows, fed a probiotic-supplemented diet  
138 (PRO/PRO). Probiotic supplementation consisted of  $\sim 1 \times 10^9$  CFU of *B. altitudinis*  
139 WIT588 spores administered daily, as outlined below. Probiotic supplementation  
140 ceased at D28 pw, but pigs were monitored until the end of the finisher period ( $\sim D127$   
141 pw). A starter/link diet was fed for the first 28 days pw, followed by a weaner diet until  
142 D55 pw, and thereafter a finisher diet was fed until slaughter at D127 pw.

143 The ingredient composition and nutrient content of all sow and offspring diets are  
144 shown in **Table 1**. The diets were manufactured in the Teagasc feed mill (Moorepark,  
145 Fermoy, Co. Cork) and were formulated to meet or exceed National Research Council  
146 recommendations (NRC, 2012)<sup>(34)</sup> for pigs at the relevant stage of the production cycle.  
147 All starter/link diets were formulated with 10.74 MJ/kg net energy and 14.0 g/kg  
148 standardised ileal digestible lysine (SID Lys) using the same ingredients. Similarly, the

149 weaner diet was formulated with 10.55 MJ/kg net energy and 11.49 g/kg SID Lys. The  
150 finisher diet was formulated with 9.80 MJ/kg net energy and 9.97 g/kg SID Lys. All  
151 diets were fed in 3 mm pellet form. Sows were fed 2.7 kg/day of feed up to the day of  
152 farrowing and thereafter were provided with *ad libitum* access to feed from a trough  
153 using a computerised feed delivery system (DryExact Pro, Big Dutchman, Vechta,  
154 Germany). Water was available on an *ad libitum* basis to sows during gestation and  
155 lactation from a single-bite drinker in the feed trough and to suckling piglets from a  
156 bowl in the farrowing pen. Suckling piglets were offered creep feed in pelleted form  
157 from D12 of age to weaning. At all stages post-weaning, pigs were provided with *ad*  
158 *libitum* access to feed from a 30 cm wide stainless-steel feeder (O'Donovan  
159 Engineering, Coachford, Co. Cork, Ireland) and to water from one nipple-in-bowl  
160 drinker (BALP, Charleville-Mezieres, Cedex, France). Representative samples were  
161 taken from all diets and analysed for dry matter, ash, crude protein, total oil, crude fibre,  
162 and neutral detergent fibre by Sciantec Analytical Services Limited, Cawood, UK.

163

#### 164 ***Preparation and administration of probiotic spores***

165 *Bacillus altitudinis* WIT588 is a rifampicin resistant variant of a seaweed-derived  
166 isolate (WIT572; NCIMB 43558) characterized, both *in vitro* and *in vivo* as a probiotic  
167 for pigs, used to facilitate enumeration in the porcine gastrointestinal tract<sup>(26,35,36)</sup>. The  
168 strain was first referred to as *B. pumilus* on the basis of sequencing of the *gyrB* and *pyrE*  
169 genes<sup>(26)</sup>, but has since been identified as *B. altitudinis* on the basis of whole genome  
170 sequencing (unpublished data). The *B. altitudinis* WIT588 spore suspension used in the  
171 current feeding trial was prepared according to the nutrient exhaustion method  
172 described by Prieto *et al.* (2014)<sup>(36)</sup> and the spores were suspended in sterile water. The  
173 concentration was then determined using a haemocytometer and adjusted to  $\sim 10^9$   
174 spores/ml. Aliquots of this spore suspension were stored at  $-20^\circ\text{C}$  until use. Probiotic  
175 spores were administered once daily in the morning to the respective treatment groups.  
176 The doses used for sows and weaned pigs, as outlined above, were calculated based on  
177 data from previous experiments and doses used for comparable commercially available  
178 probiotics. The amount of spore suspension required each day was thawed over night at  
179  $4^\circ\text{C}$ . On the morning of administration, spore suspensions were diluted in distilled  
180 water to the required dose and top-dressed onto the feed in a final volume of 4 ml for

181 gestating sows and weaned pigs and 12 ml for lactating sows. The same volume of  
182 sterile water was top-dressed onto the feed of CON pigs not administered probiotic.

183

#### 184 *Animal housing and management*

185 PRO sows were housed separately from CON sows, with two farrowing rooms for PRO  
186 sows, each with 7 pens per room, and one room for CON sows with 14 pens per room.  
187 Farrowing pens (2.5 m × 1.8 m) had a farrowing crate on a partially slatted floor with a  
188 heated floor pad for piglets. The temperature of the farrowing rooms was maintained at  
189 ~24°C at farrowing and gradually reduced to 21°C by D7 of lactation. Each room was  
190 illuminated by daylight and artificial light. The temperature inside the building was  
191 automatically controlled. Ventilation was via punched ceiling ventilation with air  
192 exhausted via a variable speed fan linked to a thermostat and controlled automatically  
193 via a controller (135-L2 Pro climate computer; Big Dutchman, Vechta, Germany)  
194 outside each room.

195 At weaning, piglets were housed in same gender pairs in 72 pens ( $n=2$  pigs/pen) across  
196 4 rooms. Each room contained 24 pens (1.2 m × 0.9 m), with treatments distributed  
197 equally across rooms. Pens were fully slatted with plastic flooring (Faroex, Manitoba,  
198 Canada). Empty pens were left between treatments to minimise probiotic cross-  
199 contamination and strict hygiene procedures were followed. Pigs were penned as pairs  
200 for the first 7 days post-weaning. A total of 40 pigs ( $n=10$ /treatment; one pig from each  
201 of 10 pen pair replicates per treatment) were sacrificed by captive bolt stunning  
202 followed by exsanguination on D8 pw to facilitate sampling of digesta and intestinal  
203 tissue. To coincide with this, one pig from each of the remaining pairs of pigs was  
204 removed from the trial at this time also and the remaining piglets ( $n=72$ ) were  
205 individually penned until slaughter at D127 pw. The temperature of the weaner rooms  
206 was maintained at 28°C for the first 7 days pw, gradually reduced to 22°C by D28 pw  
207 and maintained at 22°C until D56 pw. Temperature and ventilation were controlled by  
208 a hot air heating system and an exhaust fan drawing air from under slat level connected  
209 to a controller (Stienen PCS 8400; Stienen BV, Nederweert, the Netherlands). At D56  
210 pw, pigs were moved to one of 4 finisher rooms, each with 18 pens/room, where they  
211 were individually penned in fully slatted pens (1.81 m × 1.18 m) until the end of the  
212 experimental period (D127 pw). Pigs were kept in the same order as in the weaner  
213 rooms but without the empty pen between treatments. Finisher rooms were ventilated

214 with fans and air inlets controlled by a Stienen PCS 8200 controller (Stienen BV). Air  
215 temperature was maintained at 20 to 22°C. Sows and piglets were observed closely at  
216 least twice daily. Any pig showing signs of ill health was treated as appropriate and this  
217 was recorded. All veterinary treatments were recorded, including identity of pig,  
218 symptom, medication used and dosage.

219

### 220 ***Data recording and sampling***

221 During sampling and weighing of sows and offspring, strict hygienic measures were  
222 taken to prevent cross-contamination between treatments. CON pigs not receiving  
223 probiotic were handled first, followed by PRO treatment groups. Gloves were changed  
224 between pigs, and fresh disposable overalls were worn by all personnel prior to  
225 commencing sampling of each treatment group. All equipment, such as weighing scales  
226 and the cradle used for collection of blood samples was disinfected thoroughly with 1%  
227 Virkon® after use to prevent cross contamination at subsequent weighings/samplings.  
228 In both CON and PRO farrowing rooms and beside both PRO and CON pens within the  
229 weaner rooms, settle plates containing agar medium selective for the probiotic strain  
230 (see below) were exposed for 30 min at faecal sampling time points, and incubated with  
231 the faecal sampling plates as outlined below in order to check for the presence of the  
232 probiotic strain in the air.

233

### 234 ***Sow body weight and back fat thickness***

235 Feed intake of sows was recorded daily between D100 of gestation and D28 of  
236 lactation. Body weight and BF were recorded at the start of the experiment (D100 of  
237 gestation), on the expected farrowing date (D114 of gestation), and again at weaning of  
238 litters (~D26 of lactation). Sow BW was recorded using an electronic sow scales  
239 (EziWeigh 7i, O'Donovan Engineering, Co. Cork, Ireland). Sow BF was measured  
240 using a digital BF indicator (Renco LEAN-MEATER, Renco Corporation, Golden  
241 Valley, Minneapolis, USA) by placing the probe of the digital indicator on the back of  
242 the sow at the level of the second last rib, 6.5 cm from the side of the backbone. A  
243 reading was taken from the right and left side of the sow's back and the average of both  
244 readings was recorded.

245

246 *Colostrum and milk sampling*

247 Colostrum samples (n=12 sows/treatment) were collected by manual milking of the first  
248 four teats immediately distal to the sow's head on one side of the udder within 12 h of  
249 farrowing. On D14 of lactation, milk samples were collected from sows (n=12  
250 sows/treatment) in the same way but this time following administration of a 1 ml (10  
251 IU) intramuscular injection of oxytocin (Eurovet 247 Animal Health, Bladel,  
252 Netherlands) to induce milk let-down. All samples were stored at -20°C until analysis.

253

254 *Litter data at birth and pre-weaning piglet growth performance*

255 Reproductive parameters were recorded per litter i.e. number of piglets (total born, born  
256 alive, stillborn). The weight and sex of each piglet was recorded at birth, and each  
257 piglet was tagged for identification purposes. Thereafter, piglets were individually  
258 weighed at birth (D0), D14 and D26 *post-partum* and these data was used to determine  
259 pre-weaning piglet average daily gain (ADG). Piglet mortality between birth and  
260 weaning was also recorded.

261

262 *Post-weaning growth performance, faecal scoring and carcass measurements*

263 Growth performance of piglets was measured by weighing pigs individually and  
264 monitoring individual feed intake in order to calculate ADG, average daily feed intake  
265 (ADFI), and feed conversion ratio (FCR). Feed disappearance was recorded weekly and  
266 pigs were individually weighed at weaning (D0 pw), D14 pw, the changeover to weaner  
267 feed (D28 pw), changeover to finisher feed (D56 pw), D105 pw and immediately before  
268 slaughter (D127 pw). Pigs were fasted for 12 h prior to pre-slaughter weighing.

269 The incidence of post-weaning diarrhoea was assessed by daily faecal consistency  
270 scoring between weaning and D28 pw. The scoring system used was as follows: 0 for  
271 dry pelleted faeces; 1 for soft faeces with shape; 2 for very soft or viscous liquid faeces  
272 (mild diarrhoea); and 3 for severe diarrhoea with or without blood.

273 Pigs were slaughtered at  $\sim 123.5 \pm 1.38$  kg SEM live-weight by CO<sub>2</sub> stunning followed  
274 by exsanguination. Carcass weight was estimated by multiplying the weight of the hot  
275 eviscerated carcass 45 min after slaughter by 0.98. Kill out percentage was calculated  
276 as carcass weight/live-weight at slaughter. Back fat thickness and muscle depth  
277 measured at 6 cm from the edge of the split back at the level of the 3<sup>rd</sup> and 4<sup>th</sup> last rib  
278 were determined using a Hennessy Grading Probe (Hennessy and Chong, Auckland,

279 New Zealand). Lean meat content was estimated according to the following formula:  
280 Estimated lean meat content (%) =  $60.3 - 0.847x + 0.147y$  where  $x$  = fat depth (mm);  $y$   
281 = muscle depth (mm)<sup>(37)</sup>.

282

### 283 *Faecal sampling*

284 Faecal samples were collected from sows ( $n=24$ ) directly from the rectum using gentle  
285 digital stimulation on D100 and D115 of gestation, ~D13 of lactation and at weaning of  
286 litters (~D26 of lactation). Pre-weaning, rectal swabs were taken from offspring on  
287 ~D13 of lactation ( $n=12$  pig replicates per treatment) and faecal samples were obtained  
288 by digital rectal stimulation at weaning ( $n=10$  pig replicates per treatment), D27 pw and  
289 D56 pw ( $n=10$  pig replicates per treatment). Faeces were collected into sterile  
290 containers and, together with swabs, were put on ice and stored at 4°C until analysis for  
291 the administered probiotic strain (within 12 h), as outlined below.

292

### 293 *Blood sampling*

294 Blood samples were taken from sows ( $n=24$ ) by anterior vena cava/jugular  
295 venepuncture on D100 and D114 of gestation and at weaning of litters (~D26 of  
296 lactation). Piglets ( $n=10$  pig replicates per treatment) were blood sampled by anterior  
297 vena cava/jugular venepuncture on D0 pw, D28 pw and D57 pw. Blood samples were  
298 also collected from piglets sacrificed at D8 pw ( $n=10$  pig replicates per treatment)  
299 following exsanguination. In all cases, ~1-2 ml of whole blood was collected in a  
300 Vacutainer® tube containing EDTA (Becton-Dickson Ltd, Plymouth, UK) (except at  
301 sacrifice when the volume was ~9 ml) and immediately inverted a number of times to  
302 prevent clotting. Samples were kept at room temperature and haematological analysis  
303 performed within 6 h, as outlined below.

304

### 305 *Intestinal sampling*

306 After euthanasia of piglets on D8 pw ( $n=10$  pig replicates per treatment) the entire  
307 intestinal tract was immediately removed. Digesta samples from the ileum (15 cm  
308 proximal to the ileo-caecal junction), cecum (terminal tip) and rectum were collected  
309 aseptically into sterile containers, put on ice and stored at 4°C until analysis for the  
310 administered probiotic strain (within 12 h), as outlined below. Samples (~2 cm) of  
311 tissue were excised from the duodenum (15 cm distal to the pyloric junction), jejunum

312 (1.5 m distal to the pyloric junction) and the ileum (15 cm proximal to the ileo-caecal  
313 junction). Tissue samples were rinsed in phosphate buffered saline (PBS) immediately  
314 post-harvest and placed in No-Tox, an alcohol/aldehyde fixative (Scientific Device Lab,  
315 Des Plaines, IL, USA) on a shaker for 48 h prior to histological analysis, as outlined  
316 below.

317

### 318 ***Compositional analysis of sow colostrum and milk***

319 Colostrum and milk samples were defrosted at room temperature. When fully thawed,  
320 samples were mixed by inverting several times to disrupt settled solids and mixed well.  
321 The volume of each sample was recorded prior to decanting into 50 ml tubes on ice.  
322 Sterile water was added to bring the volume up to 40 ml. Tubes were mixed thoroughly  
323 and kept on ice. Each sample was analysed in duplicate for total solids, lactose, fat,  
324 protein, true protein and casein B content by near-infrared absorption using a Bentley  
325 Dairyspec FT (Bentley Instruments, Inc., Chaska, MN, USA). Data were recorded as %  
326 (g/100g), taking the dilution factor into account.

327

### 328 ***Immunoglobulin A and Immunoglobulin G quantification in colostrum***

329 Immunoglobulin A (IgA) and Immunoglobulin G (IgG) concentrations in colostrum  
330 were determined using ELISA kits (Pig IgA and IgG ELISA Kits, Bethyl Laboratories  
331 Inc., Texas, USA). First, 200 µl of colostrum was diluted 1:2 with PBS (1X, pH 7.4)  
332 and centrifuged at 10,000 rpm for 20 min at 4°C. The fat was then removed and the  
333 supernatant was collected and diluted 1:100,000 and 1:500,000 with 1X Dilution Buffer  
334 B (Bethyl Laboratories Inc.) for IgA and IgG analyses, respectively. The rest of the  
335 analysis was performed according to the manufacturer's protocol. All colostrum  
336 samples were analysed in duplicate. Absorbance was measured at 450 nm using a plate  
337 reader (ELx808 Absorbance Microplate Reader, BioTek, Vermont, USA). The IgA and  
338 IgG concentrations in the colostrum were obtained by reading absorbance values from  
339 standard curves prepared using standard solutions containing 1,000.0, 333.3, 111.1,  
340 37.0, 12.3, 4.1 and 1.4 ng/ml of IgA and 500.0, 250.0, 125.0, 62.5, 31.3, 15.6 and 7.8  
341 ng/ml of IgG.

342

### 343 ***Small intestinal histology***

344 Duodenal, jejunal, and ileal tissue samples were removed from the No-Tox fixative and  
345 dehydrated through a graded alcohol series, cleared with xylene and embedded in  
346 paraffin wax. Tissue samples were sliced into 5 micrometre sections using a microtome  
347 (Leica RM2135, Wetzlar, Germany), mounted on microscope slides and stained with  
348 hematoxylin and eosin for determination of gross morphological parameters of  
349 intestinal structure (villus height and width and crypt depth and width). For each pig,  
350 10 villi and 10 crypts were measured on five fields of view, where villi were attached to  
351 the lumen, and the means were utilised for statistical analysis. The goblet cell number  
352 was determined by periodic acid-Schiff staining. Positively stained periodic acid-Schiff  
353 cells were enumerated on 10 villi/sample, and the means were utilised for statistical  
354 analysis.

355

#### 356 ***Microbiological analysis of faecal and digesta samples***

357 Faecal and digesta samples and rectal swabs were homogenized and subsequently  
358 diluted in maximum recovery diluent (MRD; Merck, Darmstadt, Germany) as described  
359 by Gardiner *et al.* (2004)<sup>(38)</sup>. Appropriate dilutions were spread-plated in duplicate on  
360 brain heart infusion agar containing 3.5% NaCl, 200 µg/ml rifampicin (Sigma-Aldrich,  
361 Arklow, Co. Wicklow, Ireland), and 50 U/ml nystatin (Sigma-Aldrich) in order to  
362 enumerate the administered probiotic strain. Plates were incubated aerobically for 2  
363 days at 37°C, the colonies were counted and the counts averaged and presented as log<sub>10</sub>  
364 CFU/g of the original sample or log<sub>10</sub> CFU/swab.

365

#### 366 ***Haematological analysis of blood samples***

367 Haematological analysis was performed on whole blood using an Abbot Cell-Dyn 3700  
368 analyser (GMI-Inc, Minnesota, USA). The following parameters were measured; white  
369 blood cell (WBC) number, lymphocyte number and percentage, monocyte number and  
370 percentage, granulocyte number and percentage, eosinophil number and percentage,  
371 basophil number and percentage, red blood cell (RBC) number, haemoglobin, mean  
372 corpuscular volume, mean corpuscular haemoglobin, platelets and packed cell volume.

373

#### 374 ***Statistical analysis***

375 Power calculations were performed to determine the minimum number of observations  
376 required to detect effect sizes, using a statistical power of 80%, an  $\alpha$  level at 5% and  
377 standard deviation of variables of interest from 7 previously published studies. The  
378 power calculation indicated that 12 sows per treatment were required to see a difference  
379 of 2.5 mm in BF depth, 10 piglets were required to see a  $2 \log_{10}$  CFU/g difference in  
380 selected microbial counts between treatments and that 18 piglets were required to see a  
381  $1.5 \log_{10}$  CFU/g difference in microbial counts between treatments.

382 The experiment was a  $2 \times 2$  factorial arrangement, with the factors being maternal  
383 treatment (control or probiotic supplementation) and post-weaning treatment (control or  
384 probiotic supplementation). All data were analysed using the MIXED procedure in  
385 SAS<sup>®</sup> 9.4 (SAS Institute, Inc., Cary, NC, US), unless otherwise stated. The model  
386 included maternal treatment and post-weaning treatment as fixed effects and their  
387 interaction. Where required, data were analysed as a repeated measure with sampling  
388 day as the repeated variable and the appropriate covariance structure, as indicated by the  
389 model fit statistics, was fitted to the data. Simple main effects were obtained using the  
390 'slice' option in SAS.

391 The sow/litter was the experimental unit for sow performance, sow haematology, sow  
392 probiotic count data, colostrum and milk composition and colostrum IgA and IgG. The  
393 individual pig was the experimental unit for analysis of pre- and post-weaning pig  
394 growth performance, carcass characteristics, haematology, small intestinal morphology  
395 and probiotic count data. The normality of scaled residuals was investigated using the  
396 Shapiro-Wilk and Kolmogorov-Smirnov tests within the UNIVARIATE procedure of  
397 SAS. Differences in least square means were investigated using the t-test after Tukey  
398 adjustment for multiple comparisons. Degrees of freedom were estimated using  
399 Satterthwaite adjustment.

400 For sow performance, litter size, and pre-weaning mortality data, block was included as  
401 a random effect. The initial value (D100 of gestation) was included as a covariate in the  
402 analysis when significant in the model. Pre-weaning performance was analysed as  
403 repeated measures, including sex (male, female) as a fixed effect and block as a random  
404 effect. Birth weight was included as a covariate when significant in the model. Post-  
405 weaning performance was analysed as repeated measures, including sex (male, female)  
406 as fixed effect and weaning weight as a covariate, when significant in the model. For  
407 carcass characteristics, sex (male, female) was included as a fixed effect and BW at

408 weaning was included as a covariate when significant in the model. Counts of *B.*  
409 *altitudinis* WIT588 were analysed as repeated measurements. For the faecal counts of  
410 *B. altitudinis* WIT588 in the sows, block was included as a random effect. For the  
411 faecal counts of *B. altitudinis* WIT588 in the post-weaned piglets, the count at weaning  
412 was included as a covariate in the analysis, when significant. Haematological  
413 parameters were analysed including the initial value (D100 of gestation for sows or D0  
414 pw for the offspring) as a covariate in the analysis when significant in the model. In  
415 addition, block was included as a random effect for the haematological values of sows.  
416 The haematological parameters that were not normally distributed were further analysed  
417 to find the best fitting distribution using the GLIMMIX procedure in SAS, using a  
418 gamma distribution. For these variables, the ilink function was used to back-transform  
419 the data to the original scale. The small intestinal morphology data were analysed using  
420 sex (male, female) as a fixed effect.

421 The results are presented in the text and tables as the least square means together with  
422 the pooled standard errors of the mean. Differences between treatments were  
423 considered significant for  $P \leq 0.05$ , while  $0.05 < P \leq 0.10$  was considered as a tendency.

424

## 425 **Results**

### 426 **Sow reproductive performance and tissue mobilisation**

427 The effect of supplementing sow diets with *Bacillus altitudinis* WIT588 spores from  
428 D100 of gestation to weaning (D26 of lactation) on sow weight, BF depth, feed intake  
429 and reproductive performance is presented in **Supplementary Table S1**. There was no  
430 treatment  $\times$  day interaction for any of the variables of interest. Sows from the CON  
431 group were heavier than those in the PRO group at weaning (257.0 vs  $248.7 \pm 2.71$  kg;  
432  $P=0.03$ ). However, gestation length (114.8 vs  $114.6 \pm 0.33$  days), total born per litter  
433 (14.62 vs  $15.49 \pm 1.253$ ), live born per litter (13.50 vs  $13.97 \pm 1.170$ ), percentage of  
434 piglets live born per litter (93.3 vs  $90.8 \pm 3.25$  %), stillbirths per litter (1.15 vs  $1.51 \pm$   
435  $0.592$ ) and the numbers of piglets suckling per litter at 48h *post-partum* (14.3 vs  $14.2 \pm$   
436  $0.40$ ) were not affected by sow treatment ( $P > 0.1$ ). Although not significant, there was a  
437 numerical reduction in pre-weaning mortality (15.6 vs  $10.1 \pm 2.82$  %;  $P=0.18$ ) when the  
438 probiotic was fed and because of this a numerical increase in the number of piglets

439 weaned per litter ( $11.8$  vs  $12.6 \pm 0.55$ ;  $P=0.29$ ) in response to probiotic supplementation  
440 of sows.

441

#### 442 **Recovery of *Bacillus altitudinis* WIT588 from the faeces of sows and their litters** 443 **during lactation**

444 Faecal counts of the administered probiotic (*B. altitudinis* WIT588) from the faeces of  
445 sows during gestation and lactation and from their offspring during lactation are shown  
446 in **Table 2**. Prior to commencing probiotic treatment (D100 of gestation), *B. altitudinis*  
447 WIT588 was not detected in the faeces of either CON or PRO sows. There was a  
448 treatment  $\times$  day interaction for faecal counts of *B. altitudinis* WIT588 in sows. Counts  
449 of *B. altitudinis* WIT588 increased over time in PRO sows from D100 of gestation until  
450 D13 of lactation, declining slightly on D26 of lactation ( $P<0.001$ ). Faecal counts of *B.*  
451 *altitudinis* WIT588 were higher in PRO than in CON sows at all time points during  
452 probiotic administration (D115 of gestation, and D13 and D26 of lactation;  $P<0.001$ ), as  
453 the administered probiotic was essentially undetectable in CON sows. Although not  
454 administered the probiotic themselves, most of the offspring from PRO sows shed *B.*  
455 *altitudinis* WIT588 by D13 of age. There was a treatment  $\times$  day interaction for faecal  
456 counts of *B. altitudinis* WIT588 in the offspring of PRO sows, with probiotic counts  
457 increasing over time ( $P<0.001$ ). However, counts are not comparable, as the D13 count  
458 is presented as CFU/swab and the D26 count as CFU/g faeces. Similar effects were  
459 observed in the offspring as in the sows, in that piglets born to PRO sows had higher  
460 faecal counts of *B. altitudinis* WIT588 at D13 and D26 of age than piglets born to CON  
461 sows ( $P<0.001$ ), again due to lack of probiotic detection in the offspring from CON  
462 sows.

463

#### 464 **Haematological parameters of sows during gestation and lactation**

465 The full results for all haematological parameters measured in sows are presented in  
466 **Supplementary Table S2**. Only results for haematological parameters where there  
467 were significant treatment differences are reported in **Table 3**. There was a tendency  
468 for a treatment  $\times$  day interaction for mean corpuscular haemoglobin concentration  
469 ( $P=0.09$ ), which decreased on D114 of gestation in CON sows, increasing again at  
470 weaning (D26 of lactation). The only treatment difference found for blood cell counts

471 was for basophils. Overall, PRO sows had a higher basophil count than CON sows  
472 ( $P<0.01$ ). This was also found on D114 of gestation ( $P=0.04$ ) and a tendency for this  
473 effect was found on the day of weaning (D26;  $P=0.07$ ). Similar results were found for  
474 the overall percentage of basophils, where PRO sows had higher levels than CON sows  
475 ( $P=0.001$ ). This was also found on D114 of gestation ( $P=0.05$ ) and on the day of  
476 weaning (D26;  $P<0.01$ ). Regarding the other parameters measured, treatment  
477 differences were also observed for mean corpuscular volume and mean corpuscular  
478 haemoglobin. Overall, CON sows had higher mean corpuscular volume than PRO sows  
479 ( $P<0.001$ ) and this was also found on D114 of gestation ( $P=0.001$ ) and on the day of  
480 weaning (D26;  $P<0.01$ ). Overall, CON sows had greater mean corpuscular  
481 haemoglobin levels than PRO sows ( $P=0.001$ ) and this was also found on D114 of  
482 gestation ( $P=0.01$ ) and at weaning (D26;  $P=0.001$ ). In addition, the mean corpuscular  
483 haemoglobin concentration was higher for PRO sows than for CON sows on D114 of  
484 gestation ( $P=0.04$ ).

485

#### 486 **Colostrum and milk composition**

487 The effect of supplementing sow diets with *B. altitudinis* WIT588 spores from D100 of  
488 gestation to weaning of litters (D26 of lactation) on the composition of sow colostrum  
489 and milk is shown in **Table 4**. Colostrum composition was impacted by maternal  
490 treatment for all of the parameters measured, with the exception of fat percentage  
491 ( $P=0.75$ ) and IgA and IgG concentrations ( $P=0.46$  and  $P=0.34$ , respectively). The  
492 colostrum from PRO sows had a higher percentage of total solids ( $P=0.02$ ), protein  
493 ( $P=0.04$ ), true protein ( $P=0.05$ ) and casein B ( $P=0.05$ ), and had less lactose ( $P=0.01$ )  
494 than the colostrum from CON sows. However, milk composition was not affected by  
495 sow treatment (**Table 4**).

496

#### 497 **Pre-weaning and post-weaning pig growth performance**

498 Pig weights and average daily gains while suckling the sow were not affected by  
499 treatment (**Supplementary Table S3**;  $P>0.05$ ). Birth weight averaged  $1.47 \pm 0.029$  kg  
500 and weaning weight averaged  $7.27 \pm 0.168$  kg for piglets from both treatments.

501 The effects of *B. altitudinis* WIT588 spore supplementation to sow and piglet diets on  
502 post-weaning growth and carcass characteristics are shown in **Table 5**. No maternal

503 treatment  $\times$  post-weaning treatment  $\times$  day interaction was found. A maternal treatment  
504  $\times$  post-weaning treatment interaction was found for BW on D127 pw ( $P=0.05$ ) with a  
505 tendency for the same on D105 pw ( $P=0.07$ ) and overall ( $P=0.09$ ). On D105 pw,  
506 PRO/PRO pigs tended to be heavier than CON/PRO pigs and on D127 pw, PRO/PRO  
507 pigs were heavier than pigs born to CON sows. At D105 pw BW was  $91.7$  and  $95.2 \pm$   
508  $0.98$  kg ( $P=0.01$ ), while at D127 pw it was  $121.0$  and  $124.5 \pm 0.97$  ( $P=0.01$ ) for pigs  
509 born to CON and PRO sows, respectively. Overall, pigs born to PRO sows were  
510 heavier than pigs born to CON sows ( $P=0.01$ ). Average daily gain from D0 to D127 pw  
511 was  $890$  and  $922 \pm 10.9$  g/day ( $P=0.04$ ) for pigs born to CON and PRO sows,  
512 respectively. Overall, pigs born to PRO sows had higher ADG than pigs born to CON  
513 sows ( $P=0.04$ ). A maternal treatment  $\times$  post-weaning treatment interaction was found  
514 for FCR from D0 to D14 pw ( $P<0.001$ ), where PRO/CON pigs had better FCR than  
515 CON/PRO pigs. During this period (D0-D14 pw), pigs born to PRO sows had better  
516 FCR than those born to CON sows ( $1.28$  vs  $1.45 \pm 0.030$  g/g;  $P<0.001$ ). A maternal  
517 treatment effect for FCR was also observed for the overall period ( $P=0.02$ ). A post-  
518 weaning treatment effect was observed from D0 to D14 pw, where CON pigs had better  
519 FCR than PRO pigs ( $1.30$  vs  $1.43 \pm 0.030$  g/g;  $P<0.01$ ). A tendency for a post-weaning  
520 treatment effect was also observed from D57 to D105 pw and during the entire post-  
521 weaning period (D0-127 pw), but this time with PRO pigs having a better FCR than  
522 CON pigs [ $2.21$  vs  $2.13 \pm 0.032$  g/g ( $P=0.06$ ) and  $2.07$  vs  $2.04 \pm 0.014$  g/g ( $P=0.07$ ),  
523 respectively].

524 There was no maternal treatment  $\times$  post-weaning treatment interaction for carcass  
525 weight or carcass quality parameters ( $P>0.05$ ). Carcass weight and kill out percentage  
526 were  $90.9$  and  $94.4 \pm 1.22$  kg ( $P=0.05$ ) and  $75.0$  and  $75.9 \pm 0.187$  % ( $P<0.01$ ) for pigs  
527 born to CON and PRO sows, respectively. There was no effect of post-weaning  
528 treatment on carcass weight or carcass quality parameters ( $P>0.05$ ).

529

### 530 **Recovery of *Bacillus altitudinis* WIT588 from the faeces and intestinal digesta of** 531 **pigs post-weaning**

532 Counts of the administered *B. altitudinis* probiotic in the faeces and ileal, caecal and  
533 rectal digesta of the offspring post-weaning are shown in **Table 6**. No maternal  
534 treatment  $\times$  post-weaning treatment  $\times$  day interaction was found. A maternal treatment  
535  $\times$  post-weaning treatment interaction was found at D27 pw ( $P<0.001$ ) and a tendency

536 for this effect was also found at weaning ( $P=0.08$ ). At weaning *B. altitudinis* WIT588  
537 counts tended to be higher in the faeces of PRO/CON than PRO/PRO piglets. A  
538 maternal treatment effect was observed at weaning, where piglets born to PRO sows  
539 had higher *B. altitudinis* WIT588 counts than those born to CON sows ( $4.70$  vs  $3.00 \pm$   
540  $0.088 \log_{10}$  CFU/g faeces;  $P<0.001$ ), due to lack of detection in the latter. At D8 pw,  
541 post-weaning treatment affected counts in the intestinal digesta. *Bacillus altitudinis*  
542 WIT588 counts were higher in the ileal, caecal and rectal digesta of PRO compared to  
543 CON piglets ( $P<0.001$ ), as the administered strain was undetectable in the latter.  
544 *Bacillus altitudinis* WIT588 counts were also higher in the faeces of PRO versus CON  
545 piglets on D27 pw ( $5.93$  vs  $3.00 \pm 0.021 \log_{10}$  CFU/g faeces;  $P<0.001$ ) and there was a  
546 tendency for this effect at weaning ( $3.96$  vs  $3.74 \pm 0.088 \log_{10}$  CFU/g faeces;  $P=0.08$ ).

547

#### 548 **Faecal scoring of pigs post-weaning**

549 Statistical analysis of the probiotic effect on post-weaning diarrhoea prevalence could  
550 not be conducted, as the occurrence of faecal consistency scores higher than 0 was rare.  
551 Out of 504 faecal consistency scores given to each one of the four treatments up to D28  
552 pw, a score of 1 (soft faeces with shape) was given 45 times to the CON/CON treatment  
553 group, 28 times to the CON/PRO treatment group, 38 times to the PRO/CON treatment  
554 group and 27 times to the PRO/PRO treatment group. No scores higher than 1 were  
555 given at any time to any animal.

556

#### 557 **Haematological parameters of pigs post-weaning**

558 The effects of *Bacillus altitudinis* WIT588 supplementation to sow and piglet diets on  
559 the haematological parameters of pigs post-weaning are shown in **Table 7**. No maternal  
560 treatment  $\times$  post-weaning treatment  $\times$  day interactions were found for any of the  
561 parameters measured, except for mean corpuscular volume ( $P=0.08$ ) and mean  
562 corpuscular haemoglobin ( $P=0.09$ ) which tended to decrease with increasing age in the  
563 pigs.

564 Pigs on the post-weaning PRO treatment had higher WBC counts on D57 pw than CON  
565 pigs ( $14.62$  vs  $11.68 \pm 0.962 \times 10^3$  cells/ $\mu$ L;  $P=0.04$ ). There was a tendency for a  
566 maternal treatment  $\times$  post-weaning treatment interaction for the total lymphocyte count  
567 on D57 pw ( $P=0.10$ ). An effect of post-weaning treatment was found for the total

568 number of lymphocytes and lymphocyte percentage at D57 pw, where PRO pigs had a  
569 higher lymphocyte count and percentage than CON pigs [ $10.97$  vs  $7.29 \pm 1.145 \times 10^3$   
570 cells/ $\mu\text{L}$  ( $P=0.03$ ) and  $68.03$  vs  $59.33 \pm 2.954$  % ( $P=0.04$ ), respectively]. Similarly, the  
571 overall lymphocyte count and lymphocyte percentage tended to be higher in PRO  
572 compared to CON pigs [ $10.61$  vs  $8.42 \pm 0.822 \times 10^3$  cells/ $\mu\text{L}$  ( $P=0.06$ ) and  $68.95$  vs  
573  $61.11 \pm 2.135$  % ( $P=0.01$ ), respectively].

574 A maternal treatment  $\times$  post-weaning treatment interaction was found on D8 pw for  
575 monocyte count ( $P<0.01$ ), with counts lower in the CON/CON group than in the  
576 PRO/CON group. Likewise, a tendency for a maternal treatment  $\times$  post-weaning  
577 treatment interaction was also found for the percentage of monocytes on D8 pw  
578 ( $P=0.09$ ), with piglets from the CON/CON group having a lower percentage than their  
579 PRO/CON counterparts. This led to offspring from PRO sows having a higher  
580 monocyte percentage than pigs born to CON sows at D8 pw ( $6.65$  vs  $4.76 \pm 0.667$  %;  
581  $P=0.05$ ). In addition, pigs on the post-weaning probiotic treatment had a lower  
582 percentage of monocytes than CON pigs on D57 pw ( $7.95$  vs  $10.65 \pm 0.873$  %;  $P=0.03$ )  
583 and overall ( $6.36$  vs  $8.28 \pm 0.631$  %;  $P=0.04$ ).

584 A maternal treatment  $\times$  post-weaning treatment interaction was observed at weaning for  
585 the neutrophil count ( $P=0.05$ ), where pigs from the CON/PRO group had a higher count  
586 than PRO/PRO pigs. A tendency for a post-weaning treatment effect was observed  
587 overall for the neutrophil percentage, where probiotic-supplemented pigs had a lower  
588 percentage of neutrophils than CON pigs ( $21.90$  vs  $26.90 \pm 1.877$  %;  $P=0.07$ ).

589 There was a maternal treatment  $\times$  post-weaning treatment interaction for both the  
590 eosinophil count ( $P=0.01$ ) and percentage ( $P=0.001$ ) on D57 pw, with pigs from the  
591 PRO/CON group having a higher eosinophil count and percentage than pigs from the  
592 CON/PRO and PRO/PRO groups. A post-weaning treatment effect was also observed,  
593 with probiotic-supplemented pigs having lower eosinophil counts than CON pigs on D8  
594 pw ( $0.11$  vs  $0.16 \pm 0.017 \times 10^3$  cells/ $\mu\text{L}$ ;  $P=0.03$ ), D57 pw ( $0.15$  vs  $0.22 \pm 0.019 \times 10^3$   
595 cells/ $\mu\text{L}$ ;  $P<0.01$ ), and overall ( $0.15$  vs  $0.19 \pm 0.014 \times 10^3$  cells/ $\mu\text{L}$ ;  $P=0.050$ ).  
596 Similarly, probiotic-supplemented pigs had a lower eosinophil percentage than CON  
597 pigs on D57 pw ( $0.95$  vs  $1.89 \pm 0.140$  %;  $P<0.001$ ) and overall ( $0.97$  vs  $1.47 \pm 0.102$  %;  
598  $P=0.001$ ).

599 A maternal treatment  $\times$  post-weaning treatment interaction was found for basophil count  
600 ( $P=0.001$ ) and percentage ( $P=0.02$ ) on D8 pw, with CON/CON pigs having a lower  
601 basophil count and percentage than pigs from CON/PRO and PRO/CON groups. In  
602 addition, pigs born to CON sows had a lower basophil count than those born to PRO  
603 sows at weaning ( $0.07$  vs  $0.12 \pm 0.012 \times 10^3$  cells/ $\mu$ L;  $P=0.05$ ) and D8 pw ( $0.04$  vs  $0.06$   
604  $\pm 0.006 \times 10^3$  cells/ $\mu$ L;  $P=0.02$ ). This led to offspring from CON sows having a lower  
605 basophil percentage than those from PRO sows at weaning ( $0.58$  vs  $1.16 \pm 0.108$  %;  
606  $P=0.01$ ) and D8 pw ( $0.37$  vs  $0.55 \pm 0.058$  %;  $P=0.03$ ). An effect of post-weaning  
607 treatment was also observed for basophil percentage overall, where probiotic-  
608 supplemented pigs had a lower percentage than CON pigs ( $1.56$  vs  $2.07 \pm 0.179$  %;  
609  $P=0.05$ ).

610 At weaning, tendencies for a maternal treatment effect were observed for RBC count  
611 ( $7.82$  vs  $6.98 \pm 0.318 \times 10^6$  cells/ $\mu$ L;  $P=0.07$ ), haemoglobin ( $15.08$  vs  $13.64 \pm 0.594$   
612 g/dL;  $P=0.10$ ) and haematocrit ( $0.50$  vs  $0.45 \pm 0.018$  L/L;  $P=0.05$ ), with offspring from  
613 CON sows having higher levels than those from PRO sows. A tendency for a maternal  
614 treatment  $\times$  post-weaning treatment interaction was observed for mean corpuscular  
615 haemoglobin at weaning ( $P=0.10$ ), D57 pw ( $P=0.08$ ) and overall ( $P=0.07$ ), and for  
616 mean corpuscular haemoglobin concentration overall ( $P=0.06$ ). On D8 pw, PRO-  
617 supplemented pigs tended to have a higher mean corpuscular haemoglobin  
618 concentration than CON pigs ( $28.88$  vs  $28.43 \pm 0.186$  g/dL;  $P=0.10$ ).

619 Regarding platelet counts, a significant maternal effect was found on D8 pw, with the  
620 offspring from CON sows having a lower platelet count than those from PRO sows  
621 ( $224.25$  vs  $332.28 \pm 22.892 \times 10^3$  cells/ $\mu$ L;  $P<0.01$ ).

622

### 623 **Intestinal morphology of piglets post-weaning**

624 There was no maternal treatment  $\times$  post-weaning treatment interaction ( $P>0.05$ ) for any  
625 of the intestinal morphological parameters investigated (**Supplementary Table S4**). In  
626 addition, there was little effect of post-weaning treatment, except for an increase in  
627 villous height:crypt depth ratio in the jejunum ( $1.9$  to  $2.1 \pm 0.06$ ;  $P=0.03$ ) and an  
628 increase in villous area in the ileum ( $36786$  to  $42443 \pm 1724.3$   $\mu$ m<sup>2</sup>;  $P=0.03$ ) in response  
629 to feeding the probiotic post-weaning. For this reason, only the main effects of  
630 maternal treatment are presented in **Table 8**.

631 Pigs born to PRO sows had longer villi ( $P<0.01$ ), greater villous area ( $P<0.01$ ), deeper  
632 crypts ( $P=0.04$ ) and a tendency for greater crypt area ( $P=0.06$ ) in the duodenum than  
633 pigs born to CON sows (**Figure 1**). The offspring from PRO sows also had deeper  
634 crypts ( $P=0.04$ ) and a greater crypt area ( $P<0.01$ ) in the jejunum than those from CON  
635 sows. Ileal villous height ( $P=0.06$ ) and area ( $P=0.10$ ) tended to be greater in pigs born  
636 to PRO sows than in the offspring from CON sows.

637

## 638 **Discussion**

639 This study assessed the effect of supplementing *B. altitudinis* WIT588 spores to  
640 transition and lactating sows and/or their offspring on the growth and health of sows  
641 and their offspring. While a number of probiotic supplementation studies with a similar  
642 design have been published, piglet growth has rarely been determined after the early  
643 post-weaning period<sup>(18,20,24,27–29)</sup>. The novelty of this study lies in the fact that the  
644 offspring of probiotic-supplemented sows were followed from birth to slaughter. To  
645 our knowledge, this is the first study to date that conclusively demonstrates lifetime  
646 growth benefits in the offspring of probiotic-supplemented sows.

647 Maternal probiotic supplementation improved FCR of offspring during the first 14 days  
648 post-weaning. Improved FCR early post-weaning is considered a good indicator of  
649 improved intestinal health at this critical period<sup>(39)</sup>. This was corroborated in the present  
650 study when increased villous height was found at D8 pw in the small intestine of pigs  
651 born to probiotic-supplemented sows. This indicates increased absorptive capacity  
652 which may account for the increased lifetime growth in these animals. In fact,  
653 improved FCR early post-weaning has previously been shown to correlate well with  
654 increased lifetime growth<sup>(40)</sup>. This held true in the current study. Incremental increases  
655 in growth in offspring due to maternal probiotic supplementation were observed, with  
656 the initial increases in pig live-weight at D14, D28 and D56 pw not being statistically  
657 significant. It was only in the late finishing period (D105 and 127 pw) when increased  
658 live-weight in pigs in response to feeding probiotic to the sows became significant. The  
659 improvement in live-weight at the end of the finishing period resulted in a 3.5 kg  
660 increase in carcass weight in offspring from probiotic-supplemented versus control  
661 sows.

662 Interestingly, there was no additive effect of post-weaning supplementation of the  
663 offspring from probiotic-supplemented sows, nor were there any benefits of probiotic  
664 supplementation of weaned pigs alone. This agrees with the findings from a previous  
665 study from our group in which growth benefits in weaned pigs supplemented with this  
666 strain were only found when compared with a medicated diet containing apramycin and  
667 pharmacological levels of zinc oxide, and not when compared with the negative  
668 control<sup>(26)</sup>. The lack of effect in weaned pigs may be because commencing  
669 supplementation to pigs post-weaning might be too late to see an effect, as it is  
670 understood that there is a critical window early in life during which gut microbiota  
671 modulation is more impactful<sup>(41)</sup>. Probiotic supplementation of sow diets offers an  
672 effective means of early-life (prior to weaning) probiotic administration, as litters do not  
673 consume appreciable amounts of creep feed until ~D14 of age and oral dosing of  
674 individual piglets prior to this is not feasible on a commercial pig unit.

675 In the present study, *B. altitudinis* WIT588 was detected as early as D13 of age in  
676 suckling piglets born to sows fed this probiotic strain, even though the probiotic had not  
677 been administered to the piglets themselves. This demonstrates probiotic transfer from  
678 sows to offspring. Although, the use of *Bacillus* strains as probiotics in pig production  
679 is well documented, whether administered to weaned piglets<sup>(8,9)</sup> or to gestating sows and  
680 their offspring<sup>(18,20,24,27-29)</sup>, few studies have reported probiotic transmission from the  
681 sow to the piglet<sup>(27,28)</sup>. Although the mechanisms by which the probiotic is vertically  
682 transmitted in the present study are not fully understood, it is most likely via the faecal-  
683 oral route<sup>(42)</sup>. In fact, we hypothesise that *Bacillus* spores excreted in the sow's faeces  
684 germinate in the farrowing house environment and, due to the relatively high gastric pH  
685 in suckling piglets<sup>(43)</sup>, survive gastric transit as vegetative cells in the piglets leading to  
686 early colonization of the gut. This early colonization may also help to explain why  
687 beneficial effects are observed in these animals and not in piglets to which the probiotic  
688 spores are administered post-weaning, as it appears from our previous work that the  
689 spores do not germinate in the gut<sup>(26)</sup>. Another mechanism by which the probiotic could  
690 be vertically transmitted to the piglets is that the spores might be transferred to the  
691 piglets in dust from the sow feed or indeed via direct contact with the feed, hence  
692 bypassing faecal transplantation from the mother. However, this potential mechanism  
693 leaves little opportunity for the spores to germinate outside the pig and become

694 metabolically active and so is not considered by the authors to be as important as faecal-  
695 oral transfer.

696 Similar to the lack of persistence found in weaned piglets, which no longer shed *B.*  
697 *altitudinis* WIT588 one month after ceasing probiotic administration, this early  
698 colonization in suckling piglets was also transient. This is evidenced by the fact that *B.*  
699 *altitudinis* WIT588 was not detected in the intestinal digesta of piglets from the  
700 PRO/CON group on D8 pw, i.e. one week after contact with the probiotic-supplemented  
701 mothers had ceased. This lack of persistence post-administration is not uncommon with  
702 probiotics<sup>(12)</sup>. In addition, this early colonization in suckling piglets was not at as high a  
703 level or as consistent as when the probiotic was directly administered to weaned piglets.  
704 Not all of the piglets born to probiotic-supplemented sows shed *B. altitudinis* WIT588  
705 at both time points prior to weaning, and some of those that shed the probiotic at D13  
706 were no longer doing so at D26. However, the probiotic was recovered from all of the  
707 piglets at some point prior to weaning, and the differences in shedding may be due to  
708 variations in the level of probiotic to which the piglets were exposed and also to  
709 variations in gastric pH<sup>(43)</sup> or coprophagic behaviour<sup>(44)</sup>.

710 One possible mechanism by which the probiotic strain improved lifetime growth of the  
711 progeny of the sows to which it was administered is via modulation of colostrum  
712 composition. Although all of the measured colostrum and milk compositional values  
713 fell within reference ranges<sup>(45)</sup>, the colostrum from probiotic-fed sows had a higher  
714 protein content than that from control sows, indicating that it was of higher nutritional  
715 value<sup>(46)</sup>. In previous studies, protein, together with fat content, of milk was also  
716 increased as a result of *Bacillus* supplementation of sows<sup>(9,30)</sup>, although others reported  
717 only an increase in fat content<sup>(18)</sup>. The higher protein content of the colostrum from the  
718 probiotic-supplemented sows in the current study may have resulted from increased  
719 mobilisation of the sows' body reserves as these sows were lighter than control sows on  
720 the weaning day and lost more weight (numerically) during the lactation period.  
721 However, probiotic-supplemented sows also had to produce more milk during lactation,  
722 as they suckled more piglets to weaning. Furthermore, we do not know the exact  
723 mechanism by which probiotic supplementation increased colostrum protein content.  
724 Another avenue that we explored was that higher concentrations of immunoglobulins in  
725 the colostrum of probiotic-supplemented sows would confer increased immune  
726 protection to offspring, thereby helping to explain the observed growth benefits, the

727 numerical reduction in pre-weaning mortality and the improved intestinal morphology  
728 found in piglets born to probiotic-supplemented sows. However, maternal probiotic  
729 supplementation did not have a significant effect on the concentrations of IgA or IgG in  
730 the colostrum.

731 Interestingly, some of the haematological parameters measured in sows indicate a  
732 possible inflammatory response after the first 2 weeks of probiotic treatment (D114 of  
733 gestation) which persisted throughout the suckling period. Basophil counts in probiotic-  
734 supplemented sows were higher than those in control sows, although all values were  
735 within reference ranges, except the basophil percentage at weaning (the upper limit is  
736 2.0% and the value in probiotic-supplemented sows was 2.32%)<sup>(47)</sup>. Probiotic-  
737 supplemented sows also had lower mean corpuscular volume and less mean corpuscular  
738 haemoglobin than control sows from farrowing to weaning but values were within the  
739 normal ranges, being indicative of subtle anaemia or possible inflammation. This  
740 possible immune modulation in the sow could have affected the pigs *in utero* (despite  
741 swine placenta being epitheliochorial), which may also help to explain the improved gut  
742 health early post-weaning and the subsequent growth benefits. It has previously been  
743 reported that *Bacillus* spores can trigger immune responses in the gut<sup>(48,49)</sup>, which may  
744 protect against external pathogens. However, specific immune assays in intestinal cells  
745 are required in order to further investigate the probiotic-mediated immunomodulation  
746 hypothesised in the current study.

747 It is interesting to note that some of the haematological effects found in the sows were  
748 mirrored in the offspring. For example, piglets born to probiotic-fed sows had higher  
749 basophil counts and percentages than the offspring from control sows on the day of  
750 weaning and at D8 pw. This may have been caused by an *in utero* effect or it could be  
751 indicative of immune stimulation during the early stages of suckling due to early-life  
752 probiotic exposure. Nonetheless, this effect diminished after D8 pw and was not  
753 observed thereafter. There was no effect of post-weaning treatment with the probiotic  
754 on the haematology of pigs; however, piglets that were never exposed to *B. altitudinis*  
755 WIT588 had the lowest levels of basophils. Other significant differences of note were  
756 the effects on WBC populations found due to probiotic administration post-weaning.  
757 These included elevated total WBC and lymphocyte counts and reduced monocyte and  
758 eosinophil levels, albeit all were within reference values<sup>(50)</sup>. Interestingly, all were  
759 observed two months post-weaning (D57 pw). However, it is difficult to explain these

760 differences, because at this stage the piglets were no longer shedding *B. altitudinis*  
761 WIT588. The effects may however be residual. In any case, these post-weaning  
762 treatment-related haematological effects did not translate into improved growth,  
763 highlighting the fact that maternal supplementation is the preferred route of  
764 administration to pigs for this probiotic strain.

765

## 766 **Conclusions**

767 The data presented in this study indicate that *B. altitudinis* WIT588 dietary  
768 supplementation to sows during late gestation and lactation is more beneficial than post-  
769 weaning administration to piglets. Piglets born to sows supplemented with the probiotic  
770 displayed faecal shedding of the administered strain while suckling. This vertical  
771 transmission is rarely reported for other probiotics and demonstrates that maternal  
772 supplementation is an effective means of early-life probiotic administration. Maternal  
773 treatment improved feed efficiency in the early post-weaning period in progeny and  
774 increased live-weight at the end of the finishing period, which resulted in increased  
775 carcass weight at target slaughter age. Possible mechanisms of action are improved  
776 colostrum quality in sows, maternal immunomodulation, which was mirrored to a  
777 certain extent in the offspring, and increased small intestinal absorptive capacity in  
778 offspring early post-weaning. However, further analyses are needed to elucidate the  
779 mechanism(s) of action, including serum immunoglobulin measurements. In summary,  
780 the novelty of this study lies in the fact that the offspring of probiotic-supplemented  
781 sows were followed from birth to slaughter. The lifetime growth benefits observed  
782 offer considerable economic advantages for commercial pig producers in search of  
783 alternatives to in-feed antibiotics and pharmacological levels of zinc oxide. Work is  
784 ongoing to develop a product containing spray/freeze dried spores to facilitate  
785 formulation of the probiotic strain into commercial pig diets.

786

## 787 **Acknowledgments**

788 We thank Tomas Ryan, Florence Viard, Eoghan Gubbins-Cloney and the farm staff in  
789 the Pig Development Department at Teagasc Moorepark for assistance with the pig  
790 study. We also acknowledge Renz Ybanez, Thomas Byrne and Emily Dempsey  
791 (Waterford Institute of Technology) and David Clarke (Teagasc) for technical assistance

792 and Jim O'Donovan (Department of Agriculture Food and the Marine) for haematology  
793 analysis.

794

#### 795 **Financial support**

796 The project leading to these results was co-funded by Enterprise Ireland and the  
797 European Regional Development Fund (ERDF) under Ireland's European Structural and  
798 Investment Funds Programme 2014-2020 (grant number CF-2015-0361). Thomas  
799 Byrne who provided technical assistance was funded by a Students into Work grant  
800 from the Society for Applied Microbiology.

801

#### 802 **Conflict of Interest**

803 Gillian Gardiner, Peadar Lawlor and Alan Marsh have a patent "An isolated *Bacillus*  
804 *altitudinis* strain and its use as a probiotic" pending.

805

#### 806 **Authorship**

807 G.E.G. and P.G.L. conceived the study and, together with A.M. and S.R., designed the  
808 experiment. P.G.L and G.E.G directed the study. S.R. and P.G.L. conducted the animal  
809 experiment. G.E.G., A.M. and R.H. performed laboratory analyses together with J.P.,  
810 who also interpreted the haematology data. D.C.-P., M.A.B., S.R. and P.G.L.  
811 statistically analysed the data. D.C.-P., G.E.G. and P.G.L. interpreted the data and  
812 drafted and revised the manuscript. All authors read and approved the final version of  
813 the manuscript.

814

#### 815 **References**

- 816 1. Campbell JM, Crenshaw JD & Polo J (2013) The biological stress of early  
817 weaned piglets. *J. Anim. Sci. Biotechnol.* **4**, 19.
- 818 2. Blecha F, Pollmann DS & Nichols DA (1983) Weaning pigs at an early age  
819 decreases cellular immunity. *J. Anim. Sci.* **56**, 396–400.
- 820 3. Amezcua R, Friendship RM, Dewey CE, et al. (2002) Presentation of  
821 postweaning *Escherichia coli* diarrhea in southern Ontario, prevalence of

- 822 hemolytic *E. coli* serogroups involved, and their antimicrobial resistance patterns.  
823 *Can. J. Vet. Res.* **66**, 73–8.
- 824 4. Ruiz VLA, Bersano JG, Carvalho AF, et al. (2016) Case–control study of  
825 pathogens involved in piglet diarrhea. *BMC Res. Notes* **9**, 22.
- 826 5. Pluske JR (2013) Feed- and feed additives-related aspects of gut health and  
827 development in weanling pigs. *J. Anim. Sci. Biotechnol.* **4**, 1.
- 828 6. Gaggia F, Mattarelli P & Biavati B (2010) Probiotics and prebiotics in animal  
829 feeding for safe food production. *Int. J. Food Microbiol.* **141**, S15–S28.
- 830 7. Poulsen A-SR, Jonge N de, Nielsen JL, et al. (2018) Impact of *Bacillus* spp.  
831 spores and gentamicin on the gastrointestinal microbiota of suckling and newly  
832 weaned piglets. *PLoS One* **13**, e0207382.
- 833 8. Luise D, Bertocchi M, Motta V, et al. (2019) *Bacillus* sp. probiotic  
834 supplementation diminish the *Escherichia coli* F4ac infection in susceptible  
835 weaned pigs by influencing the intestinal immune response, intestinal microbiota  
836 and blood metabolomics. *J. Anim. Sci. Biotechnol.* **10**, 74.
- 837 9. Alexopoulos C, Georgoulakis IE, Tzivara A, et al. (2004) Field evaluation of the  
838 effect of a probiotic-containing *Bacillus licheniformis* and *Bacillus subtilis* spores  
839 on the health status, performance, and carcass quality of grower and finisher pigs.  
840 *J. Vet. Med. A. Physiol. Pathol. Clin. Med.* **51**, 306–12.
- 841 10. Nicholson WL, Munakata N, Horneck G, et al. (2000) Resistance of *Bacillus*  
842 endospores to extreme terrestrial and extraterrestrial environments. *Microbiol.*  
843 *Mol. Biol. Rev.* **64**, 548–72.
- 844 11. Setlow P (1994) Mechanisms which contribute to the long-term survival of  
845 spores of *Bacillus* species. *Soc. Appl. Bacteriol. Symp. Ser.* **23**, 49S-60S.
- 846 12. Leser TD, Knarreborg A & Worm J (2008) Germination and outgrowth of  
847 *Bacillus subtilis* and *Bacillus licheniformis* spores in the gastrointestinal tract of  
848 pigs. *J. Appl. Microbiol.* **104**, 1025–1033.
- 849 13. Hong HA, Duc LH & Cutting SM (2005) The use of bacterial spore formers as  
850 probiotics. *FEMS Microbiol. Rev.* **29**, 813–835.
- 851 14. Duc LH, Hong HA, Barbosa TM, et al. (2004) Characterization of *Bacillus*

- 852 probiotics available for human use. *Appl. Environ. Microbiol.* **70**, 2161–71.
- 853 15. Guo X, Li D, Lu W, et al. (2006) Screening of *Bacillus* strains as potential  
854 probiotics and subsequent confirmation of the in vivo effectiveness of *Bacillus*  
855 *subtilis* MA139 in pigs. *Antonie Van Leeuwenhoek* **90**, 139–46.
- 856 16. Davis ME, Parrott T, Brown DC, et al. (2008) Effect of a *Bacillus*-based direct-  
857 fed microbial feed supplement on growth performance and pen cleaning  
858 characteristics of growing-finishing pigs. *J. Anim. Sci.* **86**, 1459–1467.
- 859 17. Kyriakis SC, Georgoulakis I, Spais A, et al. (2003) Evaluation of Toyocerin, a  
860 probiotic containing *Bacillus toyoi* spores, on health status and productivity of  
861 weaned, growing and finishing pigs. *Asian-Australasian J. Anim. Sci.* **16**, 1326–  
862 1331.
- 863 18. Alexopoulos C, Karagiannidis A, Kritas SK, et al. (2001) Field evaluation of a  
864 bioregulator containing live *Bacillus cereus* spores on health status and  
865 performance of sows and their litters. *J. Vet. Med. A. Physiol. Pathol. Clin. Med.*  
866 **48**, 137–45.
- 867 19. Kyriakis SC, Tsiloyiannis VK, Vlemmas J, et al. (1999) The effect of probiotic  
868 LSP 122 on the control of post-weaning diarrhoea syndrome of piglets. *Res. Vet.*  
869 *Sci.* **67**, 223–228.
- 870 20. Alexopoulos C, Georgoulakis IE, Tzivara A, et al. (2004) Field evaluation of the  
871 efficacy of a probiotic containing *Bacillus licheniformis* and *Bacillus subtilis*  
872 spores, on the health status and performance of sows and their litters. *J. Anim.*  
873 *Physiol. Anim. Nutr. (Berl)*. **88**, 381–92.
- 874 21. Jadamus A, Vahjen W, Schafer K, et al. (2002) Influence of the probiotic strain  
875 *Bacillus cereus* var. *toyoi* on the development of enterobacterial growth and on  
876 selected parameters of bacterial metabolism in digesta samples of piglets. *J.*  
877 *Anim. Physiol. Anim. Nutr. (Berl)*. **86**, 42–54.
- 878 22. Baker AA, Davis E, Spencer JD, et al. (2013) The effect of a *Bacillus*-based  
879 direct-fed microbial supplemented to sows on the gastrointestinal microbiota of  
880 their neonatal piglets. *J. Anim. Sci.* **91**, 3390–9.
- 881 23. Kenny M, Smidt H, Mengheri E, et al. (2011) Probiotics - do they have a role in  
882 the pig industry? *Animal* **5**, 462–70.

- 883 24. Link R, Reichel P & Kyzeková P (2016) The influence of probiotics on  
884 reproductive parameters of sows and health of their sucklings. *Folia Vet.* **60**, 43–  
885 46.
- 886 25. Barba-Vidal E, Martín-Orúe SM & Castillejos L (2018) Review: Are we using  
887 probiotics correctly in post-weaning piglets? *Animal* **12**, 2489–2498.
- 888 26. Prieto ML, O’Sullivan L, Tan SP, et al. (2014) Evaluation of the efficacy and  
889 safety of a marine-derived *Bacillus* strain for use as an in-feed probiotic for  
890 newly weaned pigs. *PLoS One* **9**, e88599.
- 891 27. Taras D, Vahjen W & Simon O (2007) Probiotics in pigs — modulation of their  
892 intestinal distribution and of their impact on health and performance. *Livest. Sci.*  
893 **108**, 229–231.
- 894 28. Taras D, Vahjen W, Macha M, et al. (2005) Response of performance  
895 characteristics and fecal consistency to long-lasting dietary supplementation with  
896 the probiotic strain *Bacillus cereus* var. *toyoi* to sows and piglets. *Arch. Anim.*  
897 *Nutr.* **59**, 405–417.
- 898 29. Michiels J, Possemiers S, Degroote J, et al. (2016) Feeding *Bacillus subtilis* C-  
899 3102 to sows and suckling piglets and to weaned piglets improves parameters of  
900 gut health and feed:Gain ratio in weaners. *J. Anim. Sci.* **94**, 135–137.
- 901 30. Stamati S, Alexopoulos C, Siochu A, et al. (2006) Probiosis in sows by  
902 administration of *Bacillus toyoi* spores during late pregnancy and lactation: effect  
903 on their health status/performance and on litter characteristics. *Int. J. Probiotics*  
904 *Prebiotics* **1**, 33–40.
- 905 31. Hayakawa T, Masuda T, Kurosawa D, et al. (2016) Dietary administration of  
906 probiotics to sows and/or their neonates improves the reproductive performance,  
907 incidence of post-weaning diarrhea and histopathological parameters in the  
908 intestine of weaned piglets. *Anim. Sci. J.* **87**, 1501–1510.
- 909 32. Inatomi T, Amatatsu M, Romero-Pérez GA, et al. (2017) Dietary probiotic  
910 compound improves reproductive performance of porcine epidemic diarrhea  
911 virus-infected sows reared in a Japanese commercial swine farm under vaccine  
912 control condition. *Front. Immunol.* **8**, 1877.
- 913 33. Salmon H (1984) Immunity in the fetus and the newborn infant: a swine model.

- 914        *Reprod. Nutr. Dev.* **24**, 197–206.
- 915    34.    National Research Council (2012) *Nutrient Requirements of Swine*. 11th ed.  
916        Washington, DC: The National Academies Press.
- 917    35.    Prieto ML, O’Sullivan L, Tan SP, et al. (2012) Assessment of the  
918        bacteriocinogenic potential of marine bacteria reveals lichenicidin production by  
919        seaweed-derived *Bacillus* spp. *Mar. Drugs* **10**, 2280–99.
- 920    36.    Prieto ML, O’Sullivan L, Tan SP, et al. (2014) In vitro assessment of marine  
921        *Bacillus* for use as livestock probiotics. *Mar. Drugs* **12**, 2422–45.
- 922    37.    Department of Agriculture and Food and Rural Development (2001) *European*  
923        *Communities (Pig Carcase (Grading)) (Amendment) Regulations*. Ireland: S.I.  
924        No. 413/2001.
- 925    38.    Gardiner GE, Casey PG, Casey G, et al. (2004) Relative ability of orally  
926        administered *Lactobacillus murinus* to predominate and persist in the porcine  
927        gastrointestinal tract. *Appl. Environ. Microbiol.* **70**, 1895–906.
- 928    39.    Le Bon M, Davies HE, Glynn C, et al. (2010) Influence of probiotics on gut  
929        health in the weaned pig. *Livest. Sci.* **133**, 179–181.
- 930    40.    Saintilan R, Brossard L, Vautier B, et al. (2015) Phenotypic and genetic  
931        relationships between growth and feed intake curves and feed efficiency and  
932        amino acid requirements in the growing pig. *Animal* **9**, 18–27.
- 933    41.    Stokes CR (2017) The development and role of microbial-host interactions in gut  
934        mucosal immune development. *J. Anim. Sci. Biotechnol.* **8**, 12.
- 935    42.    Aviles-Rosa EO, Rakhshandeh A & McGlone JJ (2019) Preliminary study:  
936        depriving piglets of maternal feces for the first seven days post-partum changes  
937        piglet physiology and performance before and after weaning. *Animals* **9**, 268.
- 938    43.    Kidder DE & Manners MJ (1978) *Digestion in the pig*. Bristol: Sciencetechnica.
- 939    44.    Sansom BF & Gleed PT (1981) The ingestion of sow’s faeces by suckling  
940        piglets. *Br. J. Nutr.* **46**, 451–6.
- 941    45.    Hurley WL (2015) Composition of sow colostrum and milk. In *The gestating and*  
942        *lactating sow*, pp. 193–230. The Netherlands: Wageningen Academic Publishers.
- 943    46.    Aumaitre A & Seve B (1978) Nutritional importance of colostrum in the piglet.

- 944 *Ann. Rech. Vet.* **9**, 181–92.
- 945 47. Weiss D & Wardrop KJ (editors) (2010) *Schalm's Veterinary Hematology*. 6th  
946 ed. Ames, Iowa: Wiley & Blackwell.
- 947 48. Gialdroni-Grassi G & Grassi C (1985) Bacterial products as immunomodulating  
948 agents. *Int. Arch. Allergy Appl. Immunol.* **76 Suppl 1**, 119–27.
- 949 49. Caruso A, Flamminio G, Folghera S, et al. (1993) Expression of activation  
950 markers on peripheral-blood lymphocytes following oral administration of  
951 bacillus subtilis spores. *Int. J. Immunopharmacol.* **15**, 87–92.
- 952 50. Iowa State University's Clinical Pathology Laboratory (2011) Reference  
953 Intervals. [https://www.vetmed.iastate.edu/vpath/services/diagnostic-](https://www.vetmed.iastate.edu/vpath/services/diagnostic-services/clinical-pathology/testing-and-fees/reference-intervals)  
954 [services/clinical-pathology/testing-and-fees/reference-intervals](https://www.vetmed.iastate.edu/vpath/services/clinical-pathology/testing-and-fees/reference-intervals) (accessed October  
955 2020).
- 956 51. Sauvant D, Perez J-M & Tran G (editors) (2004) *Tables of composition and*  
957 *nutritional value of feed materials*. The Netherlands: Wageningen Academic  
958 Publishers.

**Table 1. Composition of experimental diets (on an air-dry basis; kg/tonne unless otherwise stated).**

Item	Dry Sow	Lactating Sow	Starter/link	Weaner	Finisher
Barley	753.02	269.81	62.86	257.58	384.67
Wheat	0	429.6	112	433.57	400
Maize	0	0	300	0	0
Soybean meal	89.62	196.65	255	187.92	183.01
Soya hulls	121.8	0	0	0	0
Full fat soya	0	0	70	50	0
Lactoflo <sup>1</sup>	0	0	100	0	0
Skim milk powder	0	0	25	0	0
Soya oil	11	66	40	40	9.69
Lysine HCl	2.19	4.47	5.14	5.02	3.75
DL-Methionine	0.58	1.35	2.62	1.85	0.93
L-Threonine	0.6	2.45	2.55	2.09	1.7
L-Tryptophan	0	0.71	0.97	0.27	0.15
L-Valine	0	2.34	0.26	0	0
Vitamin and mineral mix	1.5 <sup>2</sup>	1.5 <sup>2</sup>	3 <sup>3</sup>	3 <sup>3</sup>	1 <sup>4</sup>
Salt feed grade	4	5	3	3	3
Mono di-calcium phosphate	6.49	8.5	9.5	4.6	1
Limestone flour	9.08	11.5	8	11	11
Phytase <sup>5</sup>	0.1	0.1	0.1	0.1	0.1
<b>Analysed chemical composition</b>					
Dry matter	875	898	891	897	876
Crude protein	129	164	190	193	171
Fat	36.6	102.8	65.1	72.1	43.5
Crude fibre	72	26	30	27	31
Neutral detergent fibre	162	82	88	84	103
Ash	40	48	48	45	43
Lysine	8.2	11.5	15.0	13.0	11.0
Methionine	2.7	3.8	5.8	4.6	3.5
Methionine and cysteine	5.4	7.0	9.1	7.9	6.7
Threonine	5.5	8.3	10.1	8.6	7.7
Tryptophan	1.7	2.8	3.4	2.6	2.3
<b>Calculated chemical composition<sup>6</sup></b>					
Standardised ileal digestible lysine	6.60	10.67	14.00	11.49	9.97
Calcium	7.20	8.32	8.00	7.25	6.59
Digestible phosphorus	3.45	3.88	4.44	3.32	2.55
Digestible energy (MJ/kg)	13.2	15.2	15.0	14.5	13.8
Net energy (MJ/kg)	8.9	10.9	10.74	10.55	9.80

<sup>1</sup>Lactoflo 70 contains 70% lactose, 11.5% protein, 0.5% oil, 7.5% ash and 0.5% fibre (Volac, Cambridge, UK).

<sup>2</sup>Premix provided per kg of complete diet: Cu, 15 mg; Fe, 70 mg; Mn, 62 mg; Zn, 80 mg; I, 0.6 mg; Se, 0.2 mg; vitamin A, 1000 IU; vitamin D<sub>3</sub>, 1000 IU; vitamin E, 100 IU; vitamin K, 2 mg; vitamin B<sub>12</sub>, 15 µg; riboflavin, 5 mg; nicotinic acid, 12 mg; pantothenic acid, 10 mg; choline chloride, 500 mg; biotin, 200 mg; folic acid, 5 g; vitamin B<sub>1</sub>, 2 mg; vitamin B<sub>6</sub>, 3 mg.

<sup>3</sup>Premix provided per kg of complete diet: Cu, 155 mg; Fe, 90 mg; Mn, 47 mg; Zn, 120 mg; I, 0.6 mg; Se, 0.3 mg; vitamin A, 6000 IU; vitamin D<sub>3</sub>, 1000 IU; vitamin E, 100 IU; vitamin K, 4 mg; vitamin B<sub>12</sub>, 15 µg; riboflavin, 2 mg; nicotinic acid, 12 mg; pantothenic acid, 10 mg; choline chloride, 250 mg; vitamin B<sub>1</sub>, 2 mg; vitamin B<sub>6</sub>, 3 mg; Endox, 60 g.

<sup>4</sup>Premix provided per kg of complete diet: Cu, 15 mg; Fe, 24 mg; Mn, 31 mg; Zn, 80 mg; I, 0.3 mg; Se, 0.2 mg; vitamin A, 2000 IU; vitamin D<sub>3</sub>, 500 IU; vitamin E, 40 IU; vitamin K, 4 mg; vitamin B<sub>12</sub>, 15 µg; riboflavin, 2 mg; nicotinic acid, 12 mg; pantothenic acid, 10 mg; vitamin B<sub>1</sub>, 2 mg; vitamin B<sub>6</sub>, 3 mg.

<sup>5</sup>The diet contained 500 phytase units (FYT) per kg feed from RONOZYME HiPhos (DSM, Belfast, UK).

<sup>6</sup>Calculated from tabulated ingredient values<sup>(51)</sup>.

For Review Only

**Table 2. Effect of supplementing sow diets with *Bacillus altitudinis* WIT588 spores from day (D) 100 of gestation to weaning (D26 of lactation) on faecal counts ( $\log_{10}$  CFU/g) of sows and their piglets<sup>1</sup>.**

Days	Treatment		SEM <sup>1</sup>	P-value		
	CON <sup>2</sup> (No. pigs in which probiotic detected/ No. pigs sampled)	PRO <sup>3</sup> (No. pigs in which probiotic detected/ No. pigs sampled)		Treatment	Day	Treatment × Day
<b>Sows</b>						
N	12	12				
D100 Gestation	3.00 <sup>4</sup> (0/12)	3.00 (0/12)	-	-		-
D115 Gestation	3.08 (1/12)	5.93 (12/12)	0.047	<0.001		
D13 Lactation	3.00 (0/12)	6.39 (12/12)	0.047	<0.001		
Weaning (D26 Lactation)	3.00 (0/12)	6.17 (12/12)	0.047	<0.001		
Overall			0.034	<0.001	<0.001	<0.001
<b>Piglets during lactation</b>						
N	20	20				
D13 <sup>5</sup>	3.00 (0/20)	3.47 (12/20)	0.075	<0.001		
D26 <sup>6</sup>	3.00 (0/20)	4.79 (16/20)	0.080	<0.001		
Overall			0.055	<0.001	<0.001	<0.001

<sup>1</sup>Least square means and pooled standard errors of the mean (SEM).

<sup>2</sup>CON: non-probiotic supplemented sows; <sup>3</sup>PRO: probiotic-supplemented sows.

<sup>4</sup>The limit of detection of the assay for *B. altitudinis* WIT588 was 1000 CFU/g faeces or /swab. Values below the limit of detection were recorded as 3.00  $\log_{10}$  CFU/g faeces or /swab.

<sup>5</sup>Counts are from rectal swabs and are presented as  $\log_{10}$  CFU/swab.

<sup>6</sup>A rectal swab was taken from three pigs in the probiotic treatment group due to insufficient faecal sample. Probiotic was detected in these animals but the counts were excluded from the statistical analysis.

**Table 3. Effect of supplementing sow diets with *Bacillus altitudinis* WIT588 spores from day (D) 100 of gestation to weaning (D26 of lactation) on haematological parameters of sows<sup>1</sup>.**

Blood parameters	Day	Treatment			P-value		
		CON <sup>2</sup>	PRO <sup>3</sup>	SEM	Treat- ment	Day	Treat- ment × Day
N		12	12				
Basophils (×10 <sup>3</sup> cells/μL)	G100	0.10	0.11	0.013	0.54		
	G114	0.11	0.17	0.024	<b>0.04</b>		
	W26	0.17	0.22	0.022	0.07		
	Mean	0.14	0.20	0.018	<b>&lt;0.01</b>	<b>&lt;0.01</b>	0.72
Basophils (%) <sup>4</sup>	G100	1.11	1.36	0.127	0.19		
	G114	1.24	1.81	0.207	<b>0.05</b>		
	W26	1.58	2.32	0.188	<b>&lt;0.01</b>		
	Mean	1.41	2.06	0.155	<b>0.001</b>	<b>0.02</b>	0.61
Mean corpuscular volume (fL)	G100	63.52	62.77	0.601	0.25		
	G114	66.18	63.88	0.474	<b>0.001</b>		
	W26	65.01	63.23	0.431	<b>&lt;0.01</b>		
	Mean	65.60	63.55	0.357	<b>&lt;0.001</b>	<b>0.03</b>	0.51
Mean corpuscular haemoglobin (pg/cell)	G100	19.90	19.57	0.197	0.13		
	G114	20.47	19.93	0.154	<b>0.01</b>		
	W26	20.20	19.54	0.139	<b>0.001</b>		
	Mean	20.34	19.74	0.113	<b>0.001</b>	<b>0.02</b>	0.65
Mean corpuscular haemoglobin concentration (g/dL)	G100	31.33	31.14	0.220	0.56		
	G114	30.89	31.23	0.122	<b>0.04</b>		
	W26	31.02	31.00	0.111	0.91		
	Mean	30.96	31.12	0.093	0.14	0.62	0.09

G100: Day 100 of gestation; G114: day 114 of gestation; W26: weaning (day 26 of lactation).

<sup>1</sup>Least square means and pooled standard errors of the mean (SEM).

<sup>2</sup>CON: non-probiotic supplemented sows; <sup>3</sup>PRO: probiotic-supplemented sows.

<sup>4</sup>Percentages are based on the differential count of white blood cells.

**Table 4. Effect of supplementing sow diets with *Bacillus altitudinis* WIT588 spores from day (D) 100 of gestation to weaning (D26 of lactation) on the composition of sow colostrum and milk<sup>1</sup>.**

	Treatment			<i>P</i> -value
	CON <sup>2</sup>	PRO <sup>3</sup>	SEM	
N	12	12		
<b>Colostrum</b>				
Total solids (%)	21.97	24.01	0.581	<b>0.02</b>
Lactose (%)	2.06	1.52	0.128	<b>&lt;0.01</b>
Fat (%)	3.94	4.14	0.430	0.75
Protein (%)	14.25	16.56	0.759	<b>0.04</b>
True protein (%)	13.83	16.18	0.791	<b>0.05</b>
Casein B (%)	11.98	14.08	0.717	<b>0.05</b>
Immunoglobulin A (mg/ml)	18.06	21.40	3.120	0.46
Immunoglobulin G (mg/ml)	79.79	96.42	12.157	0.34
<b>Milk<sup>4</sup></b>				
Total solids (%)	18.91	18.56	0.500	0.63
Lactose (%)	5.23	5.22	0.130	0.93
Fat (%)	7.42	6.74	0.524	0.37
Protein (%)	4.78	4.89	0.116	0.49
True protein (%)	4.25	4.41	0.115	0.34
Casein B (%)	3.34	3.47	0.111	0.45

<sup>1</sup>Least square means and pooled standard errors of the mean (SEM).

<sup>2</sup>CON: non-probiotic supplemented sows; <sup>3</sup>PRO: probiotic-supplemented sows.

<sup>4</sup>Milk was sampled 14 days *post-partum*.

**Table 5. Effect of *Bacillus altitudinis* WIT588 spore supplementation to sow and piglet diets on post-weaning growth and carcass characteristics<sup>1</sup>.**

Maternal Post-weaning (pw)	Day (pw)	Control	Control	Probiotic	Probiotic	SEM	<i>P</i> -value					
		Control	Probiotic	Control	Probiotic		Maternal	pw	Maternal × pw	Day	Maternal × pw × Day	
N		18	18	18	18							
Mortality <sup>6</sup>		0	1	0	0							
Off trial <sup>7</sup>		2	2	2	0							
Body weight (kg)	0 <sup>‡</sup>	8.1	8.7	8.1	8.4	0.36	0.62	0.16	0.72			
	14	11.8	10.9	11.8	11.3	1.31	0.89	0.57	0.95			
	28	18.8	17.4	18.9	18.6	1.32	0.62	0.50	0.84			
	56	44.4	40.5	42.9	43.1	1.34	0.68	0.16	0.23			
	105	92.7 <sup>AB</sup>	90.8 <sup>A</sup>	95.1 <sup>AB</sup>	95.4 <sup>B</sup>	1.39	<b>0.01</b>	0.55	0.07			
	127	121.1 <sup>A</sup>	120.9 <sup>A</sup>	123.4 <sup>AB</sup>	125.6 <sup>B</sup>	1.38	<b>0.01</b>	0.47	<b>0.05</b>			
	Overall					0.60	<b>&lt;0.01</b>	0.27	0.09	<b>&lt;0.001</b>		0.88
ADG (g/day)	0-14	229	200	232	210	24.9	0.80	0.31	0.77			
	15-28	502	465	509	519	25.1	0.22	0.60	0.47			
	29-56	910	818	862	874	25.5	0.87	0.13	0.10			
	57-105	1019	1030	1065	1067	26.5	0.12	0.80	0.46			
	106-127	1303	1365	1365	1375	26.3	0.17	0.17	0.19			
	Overall					11.5	<b>0.04</b>	0.55	0.40	<b>&lt;0.001</b>		0.26
ADFI (g/day)	0-14	303	282	284	271	42.0	0.72	0.68	0.96			
	15-28	641	600	648	637	42.3	0.61	0.54	0.86			
	29-56	1353	1193	1259	1288	43.0	0.99	0.13	0.08			
	57-105	2293	2170	2288	2300	44.7	0.17	0.21	0.14			
	106-127	3230	3273	3309	3336	44.3	0.11	0.43	0.35			
	Overall					19.4	0.15	0.19	0.08	<b>&lt;0.001</b>		0.38

Maternal Post-weaning (pw)	Control Control	Control Probiotic	Probiotic Control	Probiotic Probiotic	SEM	P-value					
						Day (pw)	CON/CON <sup>2</sup>	CON/PRO <sup>3</sup>	PRO/CON <sup>4</sup>	PRO/PRO <sup>5</sup>	Maternal pw
	0-127	1874	1795	1884	1883	33.7	0.15	0.24	0.26		
Feed conversion ratio (g/g)	0-14	1.37 <sup>ab</sup>	1.53 <sup>a</sup>	1.22 <sup>b</sup>	1.33 <sup>ab</sup>	0.042	<0.001	<0.01	<0.001		
	15-28	1.28	1.31	1.28	1.23	0.042	0.35	0.78	0.63		
	29-56	1.49	1.45	1.47	1.47	0.043	0.95	0.69	0.94		
	57-105	2.26	2.09	2.16	2.16	0.045	0.68	0.06	0.07		
	106-127	2.51	2.39	2.46	2.46	0.044	0.91	0.18	0.33		
	Overall					0.019	0.02	0.70	0.28	<0.001	0.22
	0-127	2.09	2.03	2.05	2.04	0.019	0.41	0.07	0.19		
<b>Carcass characteristics</b>											
	Carcass weight (kg)	91.7	90.1	93.0	95.9	1.73	0.05	0.71	0.21		
	Kill out (%)	75.1	75.0	75.5	76.3	0.27	<0.01	0.15	0.13		
	Lean meat (%)	53.8	54.6	54.6	54.0	0.47	0.86	0.81	0.15		
	Muscle (mm)	47.7	48.7	51.8	49.7	1.61	0.12	0.73	0.34		
	Fat (mm)	16.0	15.1	15.8	16.0	0.60	0.51	0.58	0.33		

ADG: average daily gain; ADFI: average daily feed intake.

<sup>1</sup>Least square means and pooled standard errors of the mean (SEM).

<sup>2</sup>CON/CON, non-probiotic supplemented sow/non-probiotic supplemented piglet; <sup>3</sup>CON/PRO, non-probiotic supplemented sow/probiotic-supplemented piglet; <sup>4</sup>PRO/CON, probiotic-supplemented sow/non-probiotic supplemented piglet; <sup>5</sup>PRO/PRO, probiotic-supplemented sow/probiotic-supplemented piglet.

<sup>6</sup>Mortality: Due to polyserositis and septicaemia (*Streptococcus suis* infection).

<sup>7</sup>Off trial: Pigs were removed from the trial due to lameness (PRO/CON, N=1), pneumonia (CON/CON, N=1 and CON/PRO, N=1), bloody diarrhoea (CON/CON, N=1 and PRO/CON, N=1) and abdominal hernia (CON/PRO, N=1).

<sup>a-b</sup>Values within a row that do not share a common superscript are significantly different ( $P \leq 0.05$ ).

<sup>A-B</sup>Values within a row that do not share a common superscript tended to differ ( $P \leq 0.10$ ).

<sup>‡</sup>Day 0 pw is the day of weaning.

**Table 6. Effect of *Bacillus altitudinis* WIT588 spore supplementation to sow and piglet diets on ileal, caecal and rectal digesta counts ( $\log_{10}$  CFU/g)<sup>1</sup> of piglets euthanized on day (D) 8 post-weaning and on faecal counts at D0, D27 and D56 post-weaning.**

Maternal Post-weaning (pw)	Control	Control	Probiotic	Probiotic	SEM	<i>P</i> -value				
	Control	Probiotic	Control	Probiotic		Maternal	pw	Maternal × pw	Day	Maternal × pw × Day
	CON/CON <sup>2</sup> (No. pigs in which probiotic detected/ No. pigs sampled)	CON/PRO <sup>3</sup> (No. pigs in which probiotic detected/ No. pigs sampled)	PRO/CON <sup>4</sup> (No. pigs in which probiotic detected/ No. pigs sampled)	PRO/PRO <sup>5</sup> (No. pigs in which probiotic detected/ No. pigs sampled)						
N	10	10	10	10						
Ileum (D8 pw)	3.00 <sup>6</sup> (0/10)	5.13 (10/10)	3.00 (0/10)	5.13 (9/10)	0.153	0.99	<0.001	0.99		
Caecum (D8 pw)	3.00 (0/10)	5.48 (10/10)	3.00 (0/10)	5.37 (10/10)	0.114	0.62	<0.001	0.62		
Rectum (D8 pw)	3.00 (0/10)	5.97 (10/10)	3.00 (0/10)	6.07 (10/10)	0.065	0.44	<0.001	0.44		
N	10	10	10	10						
Weaning (D0 pw)	3.00 <sup>A</sup> (0/10)	3.00 <sup>A</sup> (0/10)	4.47 <sup>B</sup> (8/10)	4.93 <sup>C</sup> (8/10)	0.124	<0.001	0.08	0.08		
D27 pw	3.00 <sup>a</sup> (0/10)	5.95 <sup>b</sup> (10/10)	3.00 <sup>a</sup> (0/10)	5.91 <sup>b</sup> (10/10)	0.033	0.85	<0.001	<0.001		
D56 pw	3.00 (0/10)	3.00 (0/10)	3.00 (0/10)	3.00 (0/10)	0.033	0.63	0.96	0.97		
Overall					0.025	0.87	<0.001	0.57	<0.001	0.52

<sup>1</sup>Least square means and pooled standard errors of the mean (SEM).

<sup>2</sup>CON/CON, non-probiotic supplemented sow/non-probiotic supplemented piglet; <sup>3</sup>CON/PRO, non-probiotic supplemented sow/probiotic-supplemented piglet; <sup>4</sup>PRO/CON, probiotic-supplemented sow/non-probiotic supplemented piglet; <sup>5</sup>PRO/PRO, probiotic-supplemented sow/probiotic-supplemented piglet.

<sup>6</sup>The limit of detection of the assay for *B. altitudinis* WIT588 was 1000 CFU/g faeces. Values below the limit of detection were recorded as 3.00  $\log_{10}$  CFU/g faeces.

<sup>a-b</sup>Values within a row that do not share a common superscript are significantly different ( $P \leq 0.05$ ).

<sup>A-C</sup>Values within a row that do not share a common superscript tended to differ ( $P \leq 0.10$ ).

**Table 7. Effect of *Bacillus altitudinis* WIT588 spore supplementation to sow and piglet diets on haematological parameters of piglets at weaning and day 8, 28 and 57 post-weaning<sup>1</sup>.**

Maternal Post-weaning (pw)	Day (pw)	Control	Control	Probiotic	Probiotic	SEM	<i>P</i> -value				
		Control	Probiotic	Control	Probiotic		Maternal	pw	Maternal × pw	Day	Maternal × pw × Day
White blood cells (×10 <sup>3</sup> /μl)	0‡	10.51	13.37	11.94	9.83	1.390	0.47	0.85	0.08		
	8	12.76	11.92	13.63	10.22	1.555	0.74	0.17	0.40		
	28	15.66	15.40	13.33	13.55	1.522	0.18	1.00	0.60		
	57	10.34	14.05	13.20	15.23	1.363	0.13	<b>0.04</b>	0.08		
	Mean	12.73	14.71	13.26	14.37	1.159	0.92	0.19	0.70	0.11	0.43
Lymphocytes (×10 <sup>3</sup> cells/μL)	0	5.12	6.56	6.11	5.76	1.121	0.94	0.63	0.43		
	8	7.75	6.98	7.68	5.88	1.331	0.63	0.33	0.67		
	28	10.44	10.75	8.67	9.76	1.667	0.41	0.68	0.81		
	57	5.99	10.40	8.59	11.54	1.619	0.25	<b>0.03</b>	0.10		
	Mean	8.21	10.57	8.63	10.65	1.162	0.83	0.06	0.89	0.51	0.63
Lymphocytes (%) <sup>6</sup>	0	50.58	47.86	54.11	52.73	6.077	0.49	0.79	0.91		
	8	57.96	53.29	57.04	55.48	5.473	0.90	0.57	0.78		
	28	65.49	71.52	60.29	68.23	4.348	0.34	0.11	0.29		
	57	59.30	66.80	59.37	69.26	4.180	0.76	<b>0.04</b>	0.22		
	Mean	62.39	69.16	59.83	68.74	3.027	0.63	<b>0.01</b>	0.72	0.37	0.97
Monocytes (×10 <sup>3</sup> cells/μL)	0	0.71	0.81	0.88	0.63	0.130	0.89	0.54	0.17		
	8	0.45 <sup>a</sup>	0.77 <sup>ab</sup>	1.00 <sup>b</sup>	0.58 <sup>ab</sup>	0.123	0.16	0.96	<b>&lt;0.01</b>		
	28	0.83	0.67	0.76	0.69	0.135	0.85	0.42	0.86		
	57	1.10	1.17	1.20	1.05	0.130	0.91	0.78	0.84		
	Mean	0.96	0.92	0.98	0.87	0.094	0.83	0.44	0.72	<b>&lt;0.001</b>	0.41
Monocytes (%) <sup>6</sup>	0	6.44	6.32	7.06	7.49	1.063	0.41	0.90	0.80		
	8	3.78 <sup>A</sup>	5.99 <sup>AB</sup>	7.08 <sup>B</sup>	6.24 <sup>AB</sup>	0.955	0.05	0.32	0.09		

Maternal Post-weaning (pw)	Day (pw)	Control	Control	Probiotic	Probiotic	SEM	<i>P</i> -value				
		Control	Probiotic	Control	Probiotic		Maternal	pw	Maternal × pw	Day	Maternal × pw × Day
	28	5.89	4.55	5.93	4.99	1.286	0.85	0.38	0.83		
	57	11.34	8.59	9.97	7.30	1.236	0.29	<b>0.03</b>	0.13		
	Mean	8.62	6.57	7.95	6.15	0.895	0.55	<b>0.04</b>	0.89	<b>&lt;0.001</b>	0.93
Neutrophils ( $\times 10^3$ cells/ $\mu$ L)	0	4.43 <sup>AB</sup>	5.75 <sup>A</sup>	4.66 <sup>AB</sup>	3.21 <sup>B</sup>	0.714	0.10	0.72	0.05		
	8	4.36	3.99	3.85	3.62	0.519	0.40	0.58	0.92		
	28	4.13	3.43	3.47	2.98	0.407	0.19	0.15	0.30		
	57	2.85	3.07	3.21	2.78	0.392	0.93	0.79	0.86		
	Mean	3.49	3.25	3.34	2.88	0.285	0.38	0.22	0.70	0.07	0.45
Neutrophils (%) <sup>6</sup>	0	40.69	43.98	36.20	36.98	5.059	0.26	0.69	0.81		
	8	36.81	38.02	34.10	36.84	4.676	0.68	0.67	0.86		
	28	25.63	22.04	30.54	23.98	3.393	0.33	0.14	0.31		
	57	25.15	21.09	26.27	20.49	3.270	0.94	0.14	0.51		
	Mean	25.39	21.57	28.41	22.24	2.671	0.50	0.07	0.66	0.26	0.88
Eosinophils ( $\times 10^3$ cells/ $\mu$ L)	0	0.17	0.19	0.16	0.14	0.035	0.38	0.98	0.65		
	8	0.16	0.13	0.17	0.09	0.024	0.42	<b>0.03</b>	0.29		
	28	0.19	0.17	0.13	0.15	0.028	0.22	0.99	0.59		
	57	0.19 <sup>AB</sup>	0.14 <sup>A</sup>	0.26 <sup>B</sup>	0.15 <sup>A</sup>	0.027	0.14	<b>&lt;0.01</b>	<b>0.01</b>		
	Mean	0.19	0.15	0.20	0.15	0.019	0.888	<b>0.05</b>	0.71	0.19	0.19
Eosinophils (%) <sup>6</sup>	0	1.63	1.31	1.47	1.63	0.291	0.78	0.77	0.41		
	8	1.20	1.14	0.94	0.93	0.151	0.13	0.82	0.90		
	28	1.15	1.09	0.94	0.89	0.206	0.34	0.78	0.81		
	57	1.72 <sup>ab</sup>	0.89 <sup>a</sup>	2.06 <sup>b</sup>	1.02 <sup>a</sup>	0.198	0.23	<b>&lt;0.001</b>	<b>0.001</b>		
	Mean	1.43	0.99	1.50	0.95	0.145	0.903	<b>0.001</b>	0.72	<b>&lt;0.01</b>	0.71

Maternal Post-weaning (pw)	Day (pw)	Control	Control	Probiotic	Probiotic	SEM	<i>P</i> -value					
		Control	Probiotic	Control	Probiotic		Maternal	pw	Maternal × pw	Day	Maternal × pw × Day	
		CON/CON <sup>2</sup>	CON/PRO <sup>3</sup>	PRO/CON <sup>4</sup>	PRO/PRO <sup>5</sup>							
Basophils (×10 <sup>3</sup> cells/μL)	0	0.09	0.06	0.16	0.10	0.024	<b>0.05</b>	0.11	0.70			
	8	0.03 <sup>a</sup>	0.06 <sup>b</sup>	0.08 <sup>b</sup>	0.05 <sup>ab</sup>	0.009	<b>0.02</b>	0.69	<b>0.001</b>			
	28	0.23	0.15	0.26	0.21	0.039	0.27	0.13	0.27			
	57	0.27	0.28	0.24	0.22	0.038	0.22	0.88	0.63			
	Mean	0.25	0.22	0.25	0.22	0.027	0.95	0.23	0.98	0.13	0.57	
Basophils (%) <sup>6</sup>	0	0.66	0.51	1.15	1.16	0.230	<b>0.01</b>	0.64	0.61			
	8	0.26 <sup>a</sup>	0.54 <sup>b</sup>	0.60 <sup>b</sup>	0.51 <sup>ab</sup>	0.085	<b>0.03</b>	0.11	<b>0.02</b>			
	28	1.76	1.13	2.02	1.46	0.369	0.44	0.11	0.34			
	57	2.56	2.10	1.92	1.56	0.355	0.11	0.24	0.26			
	Mean	2.16	1.61	1.97	1.51	0.259	0.59	0.05	0.87	0.08	0.98	
Red blood cells (×10 <sup>6</sup> cells/μL)	0	7.94	7.71	7.02	6.93	0.450	0.07	0.72	0.88			
	8	7.10	7.03	7.25	7.15	0.190	0.48	0.64	0.94			
	28	7.03	7.20	7.09	7.16	0.173	0.96	0.48	0.90			
	57	7.19	7.22	7.01	7.19	0.169	0.56	0.53	0.81			
	Mean	7.11	7.21	7.05	7.18	0.151	0.77	0.45	0.93	0.68	0.44	
Haemoglobin (g/dL)	0	15.36	14.79	13.38	13.90	0.840	0.10	0.98	0.52			
	8	12.92	12.89	12.96	13.03	0.307	0.77	0.95	0.87			
	28	12.10	12.45	12.26	12.72	0.280	0.45	0.15	0.47			
	57	12.99	12.45	12.31	12.84	0.270	0.59	0.99	0.25			
	Mean	12.55	12.45	12.29	12.78	0.195	0.86	0.31	0.13	0.18	0.22	
Haematocrit (L/L)	0	0.51	0.49	0.44	0.46	0.024	0.05	0.98	0.55			
	8	0.45	0.45	0.46	0.45	0.011	0.90	0.61	0.76			
	28	0.40	0.42	0.41	0.42	0.010	0.48	0.15	0.48			
	57	0.43	0.42	0.41	0.43	0.010	0.67	0.83	0.58			

Maternal Post-weaning (pw)	Day (pw)	Control	Control	Probiotic	Probiotic	<i>P</i> -value						
		Control	Probiotic	Control	Probiotic	SEM	Maternal	pw	Maternal × pw	Day	Maternal × pw × Day	
	Mean	0.42	0.42	0.41	0.43	0.009	0.87	0.33	0.53	0.20	0.15	
Mean corpuscular volume (fL)	0	63.79	63.87	63.19	66.08	0.904	0.39	0.11	0.13			
	8	64.02	64.34	63.04	62.72	1.151	0.27	0.99	0.78			
	28	57.19	58.17	58.10	59.18	0.762	0.22	0.19	0.37			
	57	59.81	57.71	58.64	59.39	0.747	0.73	0.37	0.23			
	Mean	58.48	57.94	58.37	59.28	0.651	0.35	0.78	0.27	0.07	0.08	
Mean corpuscular haemoglobin (pg/cell)	0	19.38	19.25	19.12	20.12	0.328	0.37	0.20	0.10			
	8	18.22	18.42	17.86	18.26	0.325	0.43	0.36	0.75			
	28	17.16	17.28	17.25	17.75	0.233	0.24	0.20	0.31			
	57	18.08	17.25	17.50	17.83	0.230	0.98	0.28	0.08			
	Mean	17.61	17.26	17.38	17.79	0.204	0.49	0.89	0.07	<0.01	0.09	
Mean corpuscular haemoglobin concentration (g/dL)	0	30.37	30.15	30.29	30.45	0.307	0.72	0.92	0.54			
	8	28.50	28.65	28.37	29.12	0.264	0.53	0.10	0.27			
	28	29.98	29.70	29.70	29.93	0.191	0.90	0.90	0.60			
	57	30.25	29.87	29.87	30.04	0.184	0.57	0.58	0.42			
	Mean	30.12	29.78	29.78	29.99	0.137	0.64	0.64	0.06	0.18	0.96	
Platelets (×10 <sup>3</sup> cells/μL)	0	318.10	351.50	426.70	406.80	50.627	0.11	0.90	0.60			
	8	228.06	220.50	386.20	285.89	32.594	<0.01	0.16	0.26			
	28	362.07	371.50	349.61	345.03	34.682	0.58	0.95	0.94			
	57	289.40	262.96	285.10	349.16	27.984	0.16	0.58	0.21			
	Mean	323.70	312.55	315.71	347.09	25.040	0.61	0.70	0.41	<0.01	0.15	

<sup>1</sup>Least square means and pooled standard errors of the mean (SEM).

<sup>2</sup>CON/CON, non-probiotic supplemented sow/non-probiotic supplemented piglet; <sup>3</sup>CON/PRO, non-probiotic supplemented sow/probiotic-supplemented piglet; <sup>4</sup>PRO/CON, probiotic-supplemented sow/non-probiotic supplemented piglet; <sup>5</sup>PRO/PRO, probiotic-supplemented sow/probiotic-supplemented piglet.

<sup>6</sup>Percentages are based on the differential count of white blood cells.

<sup>a-b</sup>Values within a row that do not share a common superscript are significantly different ( $P \leq 0.05$ ).

<sup>A-B</sup>Values within a row that do not share a common superscript tended to differ ( $P \leq 0.10$ ).

<sup>‡</sup>Day 0 pw is the day of weaning.

For Review Only

**Table 8. Effect of supplementing sow diets with *Bacillus altitudinis* WIT588 spores from day (D) 100 of gestation to weaning (D26 of lactation) on small intestinal morphology of piglets at D8 post-weaning<sup>1</sup>.**

	Maternal treatment		SEM	P-value
	CON <sup>2</sup>	PRO <sup>3</sup>		
N	20	20		
<b>Duodenum</b>				
Goblet cells	13.8	14.9	1.14	0.52
Villous height (µm)	351.8	392.7	8.61	<b>&lt;0.01</b>
Crypt depth(µm)	177.0	190.5	4.43	<b>0.04</b>
VH:CD ratio <sup>4</sup>	2.1	2.1	0.07	0.62
Villous area (µm <sup>2</sup> )	40888	48962	1814.2	<b>&lt;0.01</b>
Crypt area (µm <sup>2</sup> )	6739	7485	269.3	0.06
<b>Jejunum</b>				
Goblet cells	8.7	10.2	0.85	0.20
Villous height (µm)	346.3	362.8	8.07	0.16
Crypt depth(µm)	175.9	189.1	4.44	<b>0.04</b>
VH:CD ratio <sup>4</sup>	2.0	2.0	0.06	0.37
Villous area (µm <sup>2</sup> )	38947	42105	1961.2	0.26
Crypt area (µm <sup>2</sup> )	6731	8075	343.7	<b>&lt;0.01</b>
<b>Ileum</b>				
Goblet cells	13.7	15.9	1.27	0.22
Villous height (µm)	325.7	345.8	7.39	0.06
Crypt depth(µm)	183.1	187.0	3.98	0.50
VH:CD ratio <sup>4</sup>	1.8	1.9	0.05	0.41
Villous area (µm <sup>2</sup> )	37552	41677	1724.3	0.10

Crypt area ( $\mu\text{m}^2$ )	7211	7659	290.6	0.28
--------------------------------	------	------	-------	------

<sup>1</sup>Least square means and pooled standard errors of the mean (SEM).

<sup>2</sup>CON: non-probiotic supplemented sows; <sup>3</sup>PRO: probiotic-supplemented sows.

<sup>4</sup>VH:CD ratio, villous height: crypt depth ratio.

For Review Only

**Figure legends**

**Figure 1.** Intestinal morphology of duodenum sections taken on day 8 post-weaning from piglets born to sows receiving the *B. altitudinis* WT588-supplemented diet (**A**) or a control diet (**B**). The black line shows the villous height measurement. Boxplots show the significant effects of the maternal treatment on the crypt depth (**C**) and villous height (**D**) of the duodenum of the offspring. Significant differences between treatments are indicated as \*\* ( $P \leq 0.01$ ) and \* ( $0.01 < P \leq 0.05$ ).

For Review Only

## Supplementary Tables

**Supplementary Table S1. Effect of supplementing sow diets with *Bacillus altitudinis* WIT588 spores from day (D) 100 of gestation to weaning (D26 of lactation) on tissue mobilisation and reproductive performance of sows<sup>1</sup>.**

Item	Days	Treatment			P-value		Treatment × Day
		CON <sup>2</sup>	PRO <sup>3</sup>	SEM	Treatment	Day	
N		12	12				
Body weight (kg)	D100 Gestation	257.10	258.61	9.337	0.84		
	D114 Gestation	283.47	278.77	2.769	0.23		
	D26 Lactation <sup>4</sup>	256.97	248.68	2.709	<b>0.03</b>		
	Overall			1.991	<b>0.02</b>	<b>&lt;0.001</b>	0.51
Back fat (mm)	D100 Gestation	17.29	18.61	0.784	0.24		
	D114 Gestation	17.01	17.38	0.413	0.53		
	D26 Lactation	14.80	14.35	0.405	0.43		
	Overall			0.300	0.92	<b>&lt;0.001</b>	0.31
Feed intake (kg)	Gestation	2.89	2.90	0.096	0.97		
	Lactation	5.75	5.84	0.096	0.51		
	Overall			0.068	0.62	<b>&lt;0.001</b>	0.66
Body weight reduction (%) <sup>5</sup>		9.89	11.48	1.292	0.24		
Back fat reduction (%) <sup>5</sup>		6.38	8.21	3.923	0.62		
<b>Reproductive performance</b>							
Gestation length (days)		114.76	114.59	0.331	0.689		
Total born		14.62	15.49	1.253	0.560		
Live born		13.50	13.97	1.170	0.735		
Live born (%)		93.32	90.76	3.247	0.543		
Stillborn		1.15	1.51	0.592	0.648		
Piglets suckling at 48h <i>post-partum</i>		14.26	14.17	0.398	0.871		
Mortality (%) <sup>6</sup>		15.61	10.14	2.815	0.183		
Weaned piglets		11.75	12.58	0.548	0.294		

<sup>1</sup>Least square means and pooled standard errors of the mean (SEM).

<sup>2</sup>CON: non-probiotic supplemented sows; <sup>3</sup>PRO: probiotic-supplemented sows.

<sup>4</sup>Day 26 of lactation was the day that litters were weaned.

<sup>5</sup>Body weight reduction and back fat reduction were calculated for the entire lactation period.

<sup>6</sup>Mortality percentage was calculated for the entire pre-weaning period.

**Supplementary Table S2. Effect of supplementing sow diets with *Bacillus altitudinis* WIT588 spores from day (D) 100 of gestation to weaning (D26 of lactation) on haematological parameters of sows<sup>1</sup>.**

Blood parameter	Day	Treatment			P-value		
		CON <sup>2</sup>	PRO <sup>3</sup>	SEM	Treat- ment	Day	Treat- ment × Day
N		12	12				
White blood cells (×10 <sup>3</sup> cells/μl)	G100	9.08	9.77	0.754	0.53		
	G114	8.37	8.90	0.659	0.56		
	W26	11.00	9.93	0.571	0.18		
	Mean	9.68	9.42	0.454	0.66	<b>&lt;0.01</b>	0.19
Lymphocytes (×10 <sup>3</sup> cells/μL)	G100	4.32	4.15	0.386	0.76		
	G114	3.31	3.88	0.255	0.11		
	W26	3.86	3.51	0.229	0.26		
	Mean	3.58	3.69	0.182	0.64	0.70	0.05
Lymphocytes (%) <sup>4</sup>	G100	45.83	46.74	2.370	0.79		
	G114	39.02	43.08	2.586	0.28		
	W26	36.27	36.37	2.319	0.98		
	Mean	37.65	39.73	1.739	0.41	0.06	0.43
Monocytes (×10 <sup>3</sup> cells/μL)	G100	0.66	0.80	0.087	0.20		
	G114	0.69	0.65	0.058	0.55		
	W26	0.67	0.71	0.051	0.62		
	Mean	0.68	0.68	0.042	0.89	0.70	0.43
Monocytes (%) <sup>4</sup>	G100	8.04	8.63	0.516	0.43		
	G114	8.22	7.57	0.563	0.40		
	W26	6.40	7.36	0.506	0.17		
	Mean	7.31	7.46	0.405	0.77	0.05	0.12
Neutrophils (×10 <sup>3</sup> cells/μL)	G100	3.45	3.32	0.355	0.79		
	G114	3.99	3.67	0.571	0.70		
	W26	5.67	4.64	0.505	0.17		
	Mean	4.83	4.16	0.384	0.23	<b>0.02</b>	0.52
Neutrophils (%) <sup>4</sup>	G100	37.28	37.05	2.602	0.95		
	G114	47.04	40.74	2.990	0.15		
	W26	51.00	49.05	2.646	0.61		
	Mean	49.02	44.90	2.001	0.16	<b>0.04</b>	0.45
Eosinophils (×10 <sup>3</sup> cells/μL)	G100	0.44	0.50	0.045	0.32		
	G114	0.35	0.37	0.073	0.82		
	W26	0.47	0.40	0.066	0.45		
	Mean	0.41	0.39	0.052	0.74	0.26	0.50
Eosinophils (%) <sup>4</sup>	G100	4.59	5.58	0.439	0.13		
	G114	4.08	4.11	0.639	0.97		

	W26	4.29	3.90	0.571	0.63		
	Mean	4.19	4.01	0.429	0.77	1.00	0.73
Basophils ( $\times 10^3$ cells/ $\mu$ L)	G100	0.10	0.11	0.013	0.54		
	G114	0.11	0.17	0.024	<b>0.04</b>		
	W26	0.17	0.22	0.022	<i>0.07</i>		
	Mean	0.14	0.20	0.018	<b>&lt;0.01</b>	<b>&lt;0.01</b>	0.72
Basophils (%) <sup>4</sup>	G100	1.11	1.36	0.127	0.19		
	G114	1.24	1.81	0.207	<b>0.05</b>		
	W26	1.58	2.32	0.188	<b>&lt;0.01</b>		
	Mean	1.41	2.06	0.155	<b>0.001</b>	<b>0.02</b>	0.61
Red blood cells ( $\times 10^6$ cells/ $\mu$ L)	G100	7.36	6.99	0.534	0.64		
	G114	5.88	5.87	0.128	0.94		
	W26	5.56	5.83	0.115	<i>0.10</i>		
	Mean	5.72	5.85	0.089	0.29	0.15	0.24
Haemoglobin (g/dL)	G100	14.55	13.61	1.081	0.56		
	G114	12.00	11.67	0.244	0.32		
	W26	11.27	11.37	0.219	0.73		
	Mean	11.64	11.52	0.175	0.61	<b>0.03</b>	0.32
Haematocrit (L/L)	G100	0.47	0.44	0.032	0.51		
	G114	0.39	0.37	0.008	0.14		
	W26	0.36	0.37	0.007	0.67		
	Mean	0.38	0.37	0.005	0.40	<i>0.05</i>	0.16
Mean corpuscular volume (fL)	G100	63.52	62.77	0.601	0.25		
	G114	66.18	63.88	0.474	<b>0.001</b>		
	W26	65.01	63.23	0.431	<b>&lt;0.01</b>		
	Mean	65.60	63.55	0.357	<b>&lt;0.001</b>	<b>0.03</b>	0.51
Mean corpuscular haemoglobin (pg/cell)	G100	19.90	19.57	0.197	0.13		
	G114	20.47	19.93	0.154	<b>0.01</b>		
	W26	20.20	19.54	0.139	<b>0.001</b>		
	Mean	20.34	19.74	0.113	<b>0.001</b>	<b>0.02</b>	0.65
Mean corpuscular haemoglobin concentration (g/dL)	G100	31.33	31.14	0.220	0.56		
	G114	30.89	31.23	0.122	<b>0.04</b>		
	W26	31.02	31.00	0.111	0.91		
	Mean	30.96	31.12	0.093	0.14	0.62	<i>0.09</i>
Platelets ( $\times 10^3$ cells/ $\mu$ L)	G100	120.80	161.51	27.197	0.31		
	G114	152.77	164.59	18.432	0.64		
	W26	240.59	239.14	16.473	0.95		
	Mean	196.68	201.87	13.474	0.76	<b>&lt;0.001</b>	0.68

<sup>1</sup>Least square means and pooled standard errors of the mean (SEM).

<sup>2</sup>CON: non-probiotic supplemented sows; <sup>3</sup>PRO: probiotic-supplemented sows.

<sup>4</sup>Percentages are based on the differential count of white blood cells.

**Supplementary Table S3. Pre-weaning growth performance of piglets born to sows fed a control or a probiotic-supplemented diet<sup>1</sup>.**

Item	Day (D)	Treatment			P-value		
		CON <sup>2</sup>	PRO <sup>3</sup>	SEM	Treatment	Day	Treatment × Day
N		153	154				
Mortality <sup>4</sup>		24	15				
Off trial <sup>5</sup>		6	3				
Body weight (kg)	Birth (D0)	1.48	1.47	0.029	0.90		
	D14	3.89	3.91	0.167	0.90		
	Weaning (D26)	7.24	7.30	0.168	0.69		
	Overall			0.150	0.71	<b>&lt;0.001</b>	0.84
Average daily gain (g)	D0-14	181.9	183.5	10.78	0.86		
		7	2	5			
	D15-26	293.6	305.0	10.86	0.21		
		8	9	3			
	Overall			9.854	0.31	<b>&lt;0.001</b>	0.44
	D0-26	233.2	236.1	11.20	0.70		
		7	3	7			

<sup>1</sup>Least square means and pooled standard errors of the mean (SEM).

<sup>2</sup>CON: non-probiotic supplemented sows; <sup>3</sup>PRO: probiotic-supplemented sows.

<sup>4</sup>Mortality: In CON group, mortality was due to overlay (N=12), starvation (N=11), and pot belly (N=1). In PRO group, mortality was due to overlay (N=5) and starvation (N=8).

<sup>5</sup>Off trial: Runt piglets (CON, N=6 and PRO, N=3) that were removed from the trial.

**Supplementary Table S4. Effect of *Bacillus altitudinis* WIT588 spore supplementation to sow and piglet diets on small intestinal morphology of piglets at day 8 post-weaning<sup>1</sup>.**

Maternal Post-weaning (pw)	Control	Control	Probiotic	Probiotic	SEM	<i>P</i> -value		
	Control	Probiotic	Control	Probiotic		Maternal	pw	Maternal × pw
	CON/CON <sup>2</sup>	CON/PRO <sup>3</sup>	PRO/CON <sup>4</sup>	PRO/PRO <sup>5</sup>				
N	10	10	10	10				
<b>Duodenum</b>								
Goblet cells	14.2	13.5	14.3	15.5	1.62	0.52	0.88	0.54
Villous height (µm)	340.9	362.7	400.7	384.7	12.18	<b>&lt;0.01</b>	0.81	0.13
Crypt depth(µm)	175.2	178.9	192.7	188.3	6.27	<b>0.04</b>	0.96	0.52
VH:CD ratio <sup>6</sup>	2.0	2.1	2.1	2.1	0.09	0.62	0.78	0.69
Villous area (µm <sup>2</sup> )	38819	42958	49822	48103	2565.7	<b>&lt;0.01</b>	0.64	0.26
Crypt area (µm <sup>2</sup> )	6531	6946	7636	7335	380.9	0.06	0.88	0.35
<b>Jejunum</b>								
Goblet cells	9.9	7.4	10.3	10.1	1.19	0.20	0.26	0.32
Villous height (µm)	346.5	346.1	345.7	379.9	11.41	0.16	0.15	0.14
Crypt depth(µm)	182.5	169.2	190.8	187.4	6.29	<b>0.04</b>	0.19	0.44
VH:CD ratio <sup>6</sup>	2.0	2.1	1.9	2.0	0.08	0.37	<b>0.03</b>	0.69
Villous area (µm <sup>2</sup> )	38151	39743	38426	45784	2773.5	0.26	0.12	0.31
Crypt area (µm <sup>2</sup> )	6918	6544	7615	8535	486.1	<b>&lt;0.01</b>	0.58	0.19
<b>Ileum</b>								
Goblet cells	11.8	15.6	15.9	15.9	1.79	0.22	0.30	0.30
Villous height (µm)	317.9	333.6	334.4	357.2	10.46	0.06	0.08	0.74
Crypt depth(µm)	180.2	186.0	182.1	191.8	5.62	0.50	0.18	0.73
VH:CD ratio <sup>6</sup>	1.8	1.9	1.9	1.9	0.07	0.41	0.48	0.85

Villous area ( $\mu\text{m}^2$ )	36571	38533	37001	46354	2438.5	0.10	<b>0.03</b>	0.14
Crypt area ( $\mu\text{m}^2$ )	7116	7307	7006	8312	411.0	0.28	0.08	0.18

<sup>1</sup>Least square means and pooled standard errors of the mean (SEM).

<sup>2</sup>CON/CON, non-probiotic supplemented sow/non-probiotic supplemented piglet; <sup>3</sup>CON/PRO, non-probiotic supplemented sow/probiotic-supplemented piglet; <sup>4</sup>PRO/CON, probiotic-supplemented sow/non-probiotic supplemented piglet; <sup>5</sup>PRO/PRO, probiotic-supplemented sow/probiotic-supplemented piglet.

<sup>6</sup>VH:CD ratio, villous height:crypt depth ratio.

For Review Only




Figure 1. Intestinal morphology of duodenum sections taken on day 8 post-weaning from piglets born to sows receiving the *B. altitudinis* WT588-supplemented diet (A) or a control diet (B). The black line shows the villous height measurement. Boxplots show the significant effects of the maternal treatment on the crypt depth (C) and villous height (D) of the duodenum of the offspring. Significant differences between treatments are indicated as \*\* ( $P \leq 0.01$ ) and \* ( $0.01 < P \leq 0.05$ ).

## The ARRIVE Essential 10

These items are the basic minimum to include in a manuscript. Without this information, readers and reviewers cannot assess the reliability of the findings.

Item	Recommendation	Section/line number, or reason for not reporting
<b>Study design</b>	1 For each experiment, provide brief details of study design including: <ol style="list-style-type: none"> <li>The groups being compared, including control groups. If no control group has been used, the rationale should be stated.</li> <li>The experimental unit (e.g. a single animal, litter, or cage of animals).</li> </ol>	
<b>Sample size</b>	2 <ol style="list-style-type: none"> <li>Specify the exact number of experimental units allocated to each group, and the total number in each experiment. Also indicate the total number of animals used.</li> <li>Explain how the sample size was decided. Provide details of any <i>a priori</i> sample size calculation, if done.</li> </ol>	
<b>Inclusion and exclusion criteria</b>	3 <ol style="list-style-type: none"> <li>Describe any criteria used for including and excluding animals (or experimental units) during the experiment, and data points during the analysis. Specify if these criteria were established <i>a priori</i>. If no criteria were set, state this explicitly.</li> <li>For each experimental group, report any animals, experimental units or data points not included in the analysis and explain why. If there were no exclusions, state so.</li> <li>For each analysis, report the exact value of <i>n</i> in each experimental group.</li> </ol>	
<b>Randomisation</b>	4 <ol style="list-style-type: none"> <li>State whether randomisation was used to allocate experimental units to control and treatment groups. If done, provide the method used to generate the randomisation sequence.</li> <li>Describe the strategy used to minimise potential confounders such as the order of treatments and measurements, or animal/cage location. If confounders were not controlled, state this explicitly.</li> </ol>	
<b>Blinding</b>	5 Describe who was aware of the group allocation at the different stages of the experiment (during the allocation, the conduct of the experiment, the outcome assessment, and the data analysis).	
<b>Outcome measures</b>	6 <ol style="list-style-type: none"> <li>Clearly define all outcome measures assessed (e.g. cell death, molecular markers, or behavioural changes).</li> <li>For hypothesis-testing studies, specify the primary outcome measure, i.e. the outcome measure that was used to determine the sample size.</li> </ol>	
<b>Statistical methods</b>	7 <ol style="list-style-type: none"> <li>Provide details of the statistical methods used for each analysis, including software used.</li> <li>Describe any methods used to assess whether the data met the assumptions of the statistical approach, and what was done if the assumptions were not met.</li> </ol>	
<b>Experimental animals</b>	8 <ol style="list-style-type: none"> <li>Provide species-appropriate details of the animals used, including species, strain and substrain, sex, age or developmental stage, and, if relevant, weight.</li> <li>Provide further relevant information on the provenance of animals, health/immune status, genetic modification status, genotype, and any previous procedures.</li> </ol>	
<b>Experimental procedures</b>	9 For each experimental group, including controls, describe the procedures in enough detail to allow others to replicate them, including: <ol style="list-style-type: none"> <li>What was done, how it was done and what was used.</li> <li>When and how often.</li> <li>Where (including detail of any acclimatisation periods).</li> <li>Why (provide rationale for procedures).</li> </ol>	
<b>Results</b>	10 For each experiment conducted, including independent replications, report: <ol style="list-style-type: none"> <li>Summary/descriptive statistics for each experimental group, with a measure of variability where applicable (e.g. mean and SD, or median and range).</li> <li>If applicable, the effect size with a confidence interval.</li> </ol>	